Der heimliche Star - ICOS - 500 Beiträge pro Seite

[Pannenoli]

Es ist schon unglaublich wie sich Icos
in diesen Tagen hält.
Es verwundert mich, wie wenig hier über diesen
Wert diskutiert wird.
Gut - bewegt sich im Moment auch nicht viel, aber
das ist wohl in diesen Tagen eher positiv einzuschätzen.
Mich würden ein paar Meinungen und charttechnische
Analysen interessieren.
Gruss PO

[Alibabus]

@panneloli
ich bin auch seit gut einem halben jahr in diesen wert investiert
schade ist nur, dass ich sie fast beim high gekauft habe
aber in seit diesem jahr ist sie sehr stabil, es verwundert mich aber auch nicht, denn der chart ist nach unten abgesichert und nach oben ist noch viel luft
nach meiner meinung ein strong buy
auch wenn es manchmal verachtet wird aber der aktionär ist mit seinem musterdepot auch in diesen wert investiert
langfristig wird sich dieser wert durchsetzten, NUR ein problem herrscht trotzdem: DER GROßE KONKURRENT PFIZER ARBEIT GENAUSO WIE ICOS AN EINEM MITTEL GEGEN IMPOTENZ UND WENN ICOS DEN KÜRZEREN ZEIHT DANN SIEHT ES NICHT SO GU AUS
würde mich davon nicht verunsichern lassen denn icos arbeit auch noch an anderen vielversprechenden mitteln
tschau alibabus

[okujawa]

Volle Zustimmung !
cu
ok

[lj68]

schaun mer mal

[Alibabus]

@all
ich sage nur: SEHR STABIL!
wenn wir die 60 nachhaltig knacken dann sieht es sehr gut aus!
tschau alibabus

[Schnippelbohne]

@Alibabus
Wie kommst Du nur darauf, daß Pfitzer auch an einem Mittel gegen Impotenz arbeitet? An welchem denn? Und weshalb sollte Icos den Kürzeren ziehen? Und wieso ist der Chart nach unten abgesichert? Und wieso ist nach oben noch jede Menge Luft?
Sorry, aber das was Du da schreibst ist absoluter Unsinn.

MfG Schnippelbohne

[Alibabus]

@schnippelbohne
pfizer arbeitet(e) auch an einem mittel gegen impotenz, nur es wies noch sehr viele nebenwirkungen auf und deshald wollen beide ein mittel mit weniger nebenwirkungen, es arbeitet sowohl pf und icos an diedsem mittel
der kurs sagt doch vieles, diese aktie war sdehr stabil als der minicrash unter den biotechs kam, guck dir mal human oder millennium an wie die abgesackt sind, man erkennt doch eine widerstandslinie bei 60E und diese versucht icos schon seit einigen zu knacken, und wenn wie vor einem halben jahr das gelingt dann ist der weg sozusagen ersteinmal bie 70E frei!
warum icos den kürzeren ziehen könnte, ich denke mal wenn ein milliardenschweres unternehmen gegen ein unternehmen wie icos mit relativ wenig geld arbeitet dann besteht zumindest die möglichkeit eines rücksetzters(guck mal auf pfizer.com, da steht alles, wenn man englisch kann:lol
das ist nur eine vermutung und ist relativ wertlos, und wenn icos verliert dann ist der weg nach unten offen?!
überzeugt, wenn nicht poste nochmal und ich versuch dich zu überzeugen....
tschau alibabus
p.s.: mehr daneben liegen als analysten kann ich ja auch nicht, außerdem ist das was ich geschrieben habe keine empfehlung, es sind nur fakten!

[Schnippelbohne]

@Alibabus
Nimm`s nicht allzu persönlich, ich halte nun mal nichts von Chartanalyse und Binsenweisheiten. Falls sich eine Aktie im Wert verändert, dann steigt sie (theoretisch zumindest nahzu unbegrenzt) oder fällt eben schlimmstenfalls auf Null.
Wenig Aussagewert, oder?

Daß Pfizer und Icos an der gleichen Substanz arbeiten halte ich für Unsinn, ich mache mir daher nicht die Mühe auf der pfizer.com nachzuschauen.
Pfizer hat Viagra und Icos wahrscheinlich bald Cilagis.

Den Kürzeren zieht in diesem Falle derjenige, der die schlechtere Substanz hat. Pfizer hat zwar viel Ansehen, Geld und Marktmacht, durch gutes Marketing kommen dann Schrottmedikamente wie z.B. Norvasc bei der Ärzteschaft kräftig in die Verordnung. Der Potenzmittelmarkt ist dagegen relativ transparent, dort wird der Patient das bessere oder ggf. billigere Mittel fordern.Icos arbeitet mit Lilly zusammen, das ist ja nun nicht gerade eine Klitsche, am Marketing solls dann wohl nicht scheitern.

Die anderen Substanzen, die Icos in der Pipeline hat sind noch in zu frühen Phasen der KliFo. Das dauert noch ewig, zumindest börsentechnisch, bis da ein Präparat zulassungsreif ist, falls es überhaupt so weit kommt.

Was meinst Du im Übrigen mit "wenn man Englich kann..lol"? Das klingt ziemlich arrogant und schnöselig. Du glaubst wohl Du wärst anderen Leuten überlegen, die kaum oder kein Englisch können, weil Du ein englischsprachige Webseite lesen kannst, oder zumiondest behauptest es zu können? Anders kann ich Dein lol leider nicht deuten.

MfG Schnippelbohne

[Alibabus]

@schnibbelbohne
das war nicht böse gemeint das lol, ich bin der meinung, wir sollten uns über soetwas auch nicht schreiten, dazu ist ja ein board zumindest da wo kontroverse meinungen aufeinandertreffen
ich meinte auch nicht das sie am selben produkt arbeiten sondern beide ein weiteres mittel gegen impotenz haben wollen, wobei das erste von pfizer noch sehr viele nebenwirkungen aufweist
ALSO; WENN ES DIR ARROGANT VORKAM DANN ENTSCHULDIGE ICH MICH; ES WAR NICHT SO GEMEINT
OK?
tschau alibabus

[Schnippelbohne]

@Alibabus
dann bin ich ja beruhigt, arrogante Boardschnösel kann ich nämlich nicht ausstehen. Also dann lieber zum Thema.

Icos hat gegenüber irgendeinem noch ausstehenden Pfizerprodukt im Moment den Vorteil, daß Cilagis vermutlich noch in diesem Jahr zugelassen wird. Nach allem was ich so gehört habe kann es Cilagis hinsichtlich der Nebenwirkungen und der Wirksamkeit durchaus mit Viagra aufnehmen bzw. es übertreffen. Eine FDA-Zulassung, die damit wahrscheinlich wird, beschleunigt dann eine Zulassung in Europa deutlich, dann teilen sich aber schon 2 den Markt. Meine Icos Aktien werden dann aber schon längst nett gestiegen sein bevor der 3. usw. kommt. Und die nächsten Firmen stehen schon mit Konkurrenzprodukten in den Startlöchern, denn die Substanz ist bekannt und kann jetzt beliebig nachgekocht und modifiziert werden. Einige Studien laufen ja schon. Naja egal, ich kann jedem nur empfehlen Icos zu halten und genüßlich zu warten. Es lohnt sich bestimmt.

Alibabus, welches Übersetzungsprogramm benutzt Du denn? Das schein mir ein witziges Ding zu sein.

Mfg Schnippelbohne

[Alibabus]

@schnippelbohne
tia, übersetzungsprogramme, da gibt es viele, ich benutze öfters systransoft.com
was hälst du eigentlich von vertex oder medigene?

tschau und good weekend!
Alibabus

[Schnippelbohne]

@Alibabus

Vertex und Medigene sind sicher attraktive Unternehmen, ich habe aber beide nicht, und ich würde im Moment auch beide nicht kaufen, solange die Stimmung (auch für Biotechs) so schlecht ist. Da kann auch B.F.vom Aktionär nichts ändern. Man braucht sich nur den Chart der letzten 12 Monate anzusehen. Wann wäre da der richtige Einstiegszeitpunkt für ein längerfristiges Investment gewesen?

Zur Zeit halte ich im Biotech-Bereich nur noch einen Fonds(DWS Biotech Typ 0), weil der nicht so schnell wie eine schlecht gewählte Einzelaktie ins Minus abschmiert (smile) sowie Qiagen und Icos. Ich rechne fest mit einer baldigen Zulassung von Cialis (ich glaub` ich habe irgendwo Cilagis geschrieben, so heißt das Zeug natürlich nicht). Da ein neues, wirklich brauchbares Potenzmittel stets was für die Medien ist (es lebe die BILD Zeitung)dürfte das den Kurs mächtig treiben, da dann jeder Trottel die Aktie auch haben möchte und dann hoffentlich unlimitiert kauft. Die Ergebnisse der Phase 3 Studien sind anscheinend o.k., es kann jetzt nicht mehr lange dauern. Also Geduld, es wird schon werden.

Persönlich würde ich im Moment generell keine Biotech-Aktie kaufen, die nicht in absehbarer Zeit ein Produkt auf den Markt bringt, d.h. mindestens eine Phase 3 Studie sollte zur Substanz schon länger laufen.

MfG Schnippelbohne

[Alibabus]

@schnippelbohne
was hast du sonst noch so für aktien oder fonds?
bin zur zeit noch in nokia drin und das schmerzt ganz schön, außerdem kurzfristig in iem und brokat!
zu icos: ich glaube auch das cialis bald zugelassen wird, weißt du eigentlich ob icos mit einem pharmaunternehmen kooperiert?
tschau und bis montag!
Alibabus

[Schnippelbohne]

@Alibabus

Icos kooperiert bezüglich Cialis mit Lilly, da Icos einen Vertriebskanal benötigt.
Zur frage was ich sonst noch so im Depot habe, in erster Linie noch Fonds im Bereich Telekommunikation, Pharma und Europa. An Einzelaktien habe ich zur Zeit nur noch Qiagen, Icos, Metabox und Internet Capital Group, die letzten beiden so als Leichen, weil sich ein Verkauf nicht mehr lohnt.

MfG Schnippelbohne

[okujawa]

Hat einer von euch eine Erklärung für den gestrigen Kursrutsch ?
Charttechnisch sieht`s jetzt nicht mehr so rosig aus.
Wir müssen heute auf jeden Fall wieder hoch.
cu
ok

[dosto]

au au au

was macht dich so sicher, dass icos die große ausnahme bleibt?
sollte jetzt tatsächlich der finale ausverkauf der biotech-aktien kommen, bin ich mir nicht so sicher, ob der markt
noch unterschiede zwischen den einzelnen aktien macht,
biotech ist dann biotech- und weg damit, habe noch niemals erlebt, dass bei einbuchen die ratio zählt-genau so wenig
wie bei der unendlich langen 90 jahre bullen-rally, von
verstand war da weit und breit nichts mehr zu sehen 1999.

gruss dosto
im grunde will ich euch denn letzten schlag nicht zumuten,
gedanklich solltet ihr euch aber damit vertraut machen,
wie so etwas aussieht, da gibts heute schon paralellen,
cmgi, insp, cmrc, ariba, inkt, etc.
oder werte mit substanz
csco, emc, glw.
wenn ich die kurse vor einem halben jahr gepostet hätte, hätte ich wahrscheinlich selber über mich gelacht.
aber finger weg, hab ich glaube schon immer gesagt.
also fazit-warum jetzt ausgerechnet soll der kleine mann
bio-tech aktien kaufen-für manche ist es noch nicht einmal
zu spät zu verkaufen, vieles bekommt ihr billiger zurück,
für die differenz, setzt auf die eisdiele im sommer-
wall street und nasaq werden boring sein.

[Alibabus]

Tia,
wieso ist icos so gefallen?
die waren in den letzten tagen ziemlich stabil und nach dem erneutenm debakel an der nasi war das kein wunder!
schau dir einfach mal amgen und biogen an, die schwergewichte im biotechindex, wenn die so massiv abgeben ziehen diese den markt mit runter
bestes bsp. ist cisco, wenn die verloren haben ging die gesamte nasi mit den bach runter!
aber ich denke icos erholt sich schnell wieder,UND WIR HABEN JA VIEL ZEIT!
tschau alibabus

[Wunram]

Viagra-Rivale funktioniert - Phase III läuft

New Cialis -- IC351 -- Study Shows Significantly Enhanced Sexual Function in 81 Percent of Men With ED Regardless of Severity

INDIANAPOLIS--(BW HealthWire)--March 19, 2001--Men with mild-to-severe erectile dysfunction (ED) may benefit from Cialis(TM) (IC351), an investigational oral treatment for ED, according to a study published in the latest issue of International Journal of Impotence Research. This first-time publication of detailed Phase II data in a peer-reviewed journal shows that on-demand treatment with Cialis, an advanced phosphodiesterase type 5 (PDE5) inhibitor, improved erections in 81 percent of men (relative to placebo: 17 percent), regardless of severity. Cialis is currently in global Phase III studies.

"Cialis is a potent and highly selective PDE5 inhibitor that both increased sexual function and was well-tolerated in a broad range of men with ED," said Harin Padma-Nathan, M.D., clinical professor of urology at the University of Southern California, Los Angeles, and lead investigator on the study. "Based on these data, Cialis has the potential to become a new treatment option for ED."

In the trial, up to 80 percent of patients with severe ED and up to 90 percent of patients with moderate ED reported significant improvement in their ability to attain and maintain an erection. Additionally, Cialis increased the percentage of successful and satisfying intercourse attempts for both men and their partners. "One of the most encouraging signs was that, as evidenced by the IIEF score, a substantial number of men who took Cialis were returned to normal sexual function," said Padma-Nathan.

Cialis Increased Erectile Function in On-Demand Study


In this study, 179 men (mean age: 56 years) with mild-to-severe ED were randomized to receive placebo or Cialis at doses up to 25 mg taken on-demand over a three-week period. The men in the trial agreed to attempt at least four sexual encounters during the treatment period.

Several measures were used to assess Cialis in a natural setting. Researchers compared baseline scores from the International Index of Erectile Function (IIEF) questionnaire (an important outcome measure reflecting overall erectile function), sexual encounter profile diaries of ED sufferers and their partners, and a global assessment question about treatment effect on erections.

The data showed that both the men in the Cialis group and their partners reported a significant increase in the number of satisfying intercourse attempts compared with the placebo group. In addition, a significant number of men taking Cialis reported an increase in the number of successful intercourse attempts compared with pretreatment. Men treated with Cialis were also able to achieve penetration and maintain erections significantly more often than those on placebo. Cialis also significantly increased the IIEF erectile function domain score compared with placebo.

In this trial, the only three treatment-related adverse events reported by more than 3 percent of men were headache, back pain and dyspepsia. These effects were generally mild to moderate and tended to decrease with time. Only two men discontinued treatment due to adverse events. No alterations of color vision were reported. Additionally, no clinically significant changes were observed in clinical laboratory values, ECGs (electrocardiogram) or blood pressure at any of the doses studied in this trial. Other clinical trials are under way to determine the overall safety profile of Cialis.

According to a recently published study in the British Journal of Urology, ED is a highly prevalent condition that affects an estimated 152 million men worldwide.(1) This includes an estimated 90 million men combined in Brazil, France, Germany, Italy, Japan, Spain, the United Kingdom and the United States.(2)

The condition is associated with a range of behavioral risk factors, such as cigarette smoking and excessive alcohol consumption, as well as numerous other medical conditions, notably diabetes and cardiovascular disease. As a result of these often age-related comorbidities, there is a higher prevalence of ED in older men. Between the ages of 40 and 70 years, for example, the incidence of severe ED triples from 5 percent to 15 percent, while moderate ED doubles from 17 percent to 34 percent.

About Lilly ICOS


Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq:ICOS) and Eli Lilly and Company (NYSE:LLY), is developing Cialis, which is currently under investigation for the treatment of both male erectile dysfunction and female sexual dysfunction (FSD). Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world`s most urgent medical needs. ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS, located in Bothell, Wash., combines capabilities in molecular, cellular and structural biology, high-throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. ICOS` disease targets include erectile dysfunction, female sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases.

This press release contains forward-looking statements about the potential of the investigational compound Cialis(TM) in treating male erectile dysfunction that reflect management`s current beliefs. However, as with any pharmaceutical under development, there are risks and uncertainties in the process of development and regulatory review. There are no guarantees that future clinical trials will confirm the preliminary results reported in this release or that the product will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see the U.S. Securities and Exchange Commission filings of ICOS and Lilly.

(1) Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase
in erectile dysfunction between 1995 and 2025 and some
possible policy consequences. BJU Int 1999; 84: 50-56.

(2) Decision Resources, Inc., Erectile Dysfunction. Pharmacor
Mosaic Service, 2000.


CONTACT: Lilly
Blair Austin, 317/277-6738
or
ICOS
Lacy Fitzpatrick, 425/415-2207

[okujawa]

Könnte jemand die Meldung eventuell übersetzen ?
Meine Englischkentnisse hängen an einigen Stellen.
Danke
cu
ok

[Alibabus]

@all
schau mal auf www.systransoft.com
da kannst du texte und einzelne wortgrupppen übersetzten!
ist zwar nicht das beste englisch aber trotzdem nützlich!
tschau alibabus

[Wunram]

also auch der Kooperationspartner Eli Lilly bestätigt positive Phase II Ergebnisse:

Eli Lilly releases positive data on anti-impotence drug

INDIANAPOLIS, March 19 (Reuters) - Drug maker Eli Lilly and Co. <LLY.N> on Monday said its experimental treatment for erectile dysfunction, Cialis, showed positive results in clinical tests.

Lilly said data from Phase II trials revealed improved erections in 81 percent of men, compared with a 17 percent improvement in the placebo group. The treatment, being developed by a joint venture between Lilly and ICOS Corp. <ICOS.O>, should compete with Pfizer Inc.`s <PFE.N> blockbuster anti-impotence drug Viagra.

Like Viagra, Cialis works by inhibiting the enzyme phosphodiesterase type 5, or PDE5, which helps control blood flow to the penis.

Cialis is currently in Phase III trials, the final stage before submission for approval with the U.S. Food and Drug Administration.

In the results of a Phase II study released in the Journal of Impotence Research, 179 patients were given either the placebo or Cialis at doses up to 25 mg, taken over a three-week period.

Lilly said Cialis increased sexual function in patients whose erectile dysfunction ranged from mild to severe.

Researchers said in November 2000 that Cialis seemed to cause fewer cases of vision distortion and facial reddening than seen in different earlier trials of Viagra.

Global sales of Viagra were about $1.34 billion in 2000, up 32 percent from 1999.

Shares of ICOS rose $1-13/16, or about 4 percent, to $47-1/4 on Monday on the Nasdaq, while shares of Lilly rose $1.56, or 2.1 percent, to $76 on the New York Stock Exchange.

(( -- Jed Seltzer New York Health Desk 212-859-1631))

REUTERS
Rtr 19:30 03-19-01

Besonders interessant:

- Marktpotenzial für die Medikamente zur Behebung von Erektionsstörungen: 1,34 Milliarden in 2000

-Nebenwirkungen durch Cialis wie Sehstörungen oder Rötungen im Gesicht scheinen weniger oft aufzutreten wie bei Viagra

Wunram

[Alibabus]

@wurman
dane für den interessanten bericht!
werden noch viel spaß mit dieser aktie haben, hoffe ich zumindest!
die korrektur heute war mal überfällig und wird gut für die nächsten anstiege sein, denn sonst würde icos auch irgendeinmal wie ein neuesmarktunternehmen platzen!
außerdem sieht es mit den meisten biotechs eh nicht so gut aus
ali

[NoUse]

Hallo ICOS Fans, der heutige Tag erfüllt mich mit Trauer einerlei, mit Freude andererseits. ICOS ist heute im Zuge der anderen BIOtecs zu unrecht vermöbelt worden, dafür bildet sich jetzt die Möglichkeit des günstigen Einstiegs.

[okujawa]

Gab es irgendwelche Neuigkeiten ? Hoffen wir mal, dass es jetzt wieder aufwärts geht und die 40$ halten, ansonsten gute Nacht. Charttechnisch sieht es nicht so berauschend aus.
cu
ok

[NoUse]

nicht verzagen, dran bleiben, sieht doch gar nicht schlecht aus.....

[Alibabus]

@all
nachdem icos kurzfristig unter die marke von 40 us dollar fiel, sah es zuesrt gar nicht so gut aus!
doch am freitag zeigte sie eher positibe reaktionen und legte sogar um über 14% zu
ich denke die 60E sollten bald überwunden sein sonst ist langsam die luft raus oder was denkt ihr?
alibabus

[Wunram]

vielleicht gibts was neues??

ICOS Scheduled At Banc of America Securities Health Care Conference

BOTHELL, Wash.--(BUSINESS WIRE)--March 26, 2001--ICOS Corporation (Nasdaq:ICOS) announced today that Paul Clark, ICOS Chairman and CEO, will speak at the Banc of America Securities Health Care Conference on March 28, 2001 at 3:30 p.m. PST. The conference is being held at the Four Seasons Hotel in Las Vegas, Nevada.

A webcast of the presentation will be available in real-time and a replay (for 24 hours). The webcast can be accessed on the ICOS website, www.icos.com, News section. Additional information on ICOS, including press releases, is also available on the website.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. These target areas include erectile dysfunction, female sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases.

CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207
http://www.businesswire.com/cnn/icos.shtml

[Wunram]

nochmal die Bestätigung der Cialis Wirkung


First Phase III Data Show Cialis -- IC351 -- Improved Sexual Function In Men With Difficult To Treat, Diabetes-Related ED

GENEVA--(BW HealthWire)--April 6, 2001--Eli Lilly and Company (NYSE:LLY)

New data to be presented at the European Association of Urology Meeting

The first Phase III study for Cialis(TM), a new PDE5 inhibitor being developed by Lilly ICOS LLC to treat erectile dysfunction (ED), showed strong results among one of the most difficult to treat populations of men with ED. The findings -- to be released tomorrow at the European Association of Urology (EAU) meeting -- demonstrated that 64 percent of men with diabetes-related ED taking Cialis 20 mg on demand reported improved erections.

"The impairment of nerve and blood vessel function that accompanies diabetes makes ED prevalent and particularly difficult to treat in this population," said Professor Inigo Saenz de Tejada, of the Foundation for Research and Development in Andrology in Madrid, Spain. "This study, alongside previously released data, suggests on demand Cialis may help most men with ED regain sexual function, regardless of cause or severity." Tejada noted that while direct comparisons cannot be made to the clinical trial results of other ED compounds in patients with diabetes, the 64 percent response rate seen in this Cialis study is impressive.

Sexual function significantly improved across all study endpoints


In this Phase III study, 216 men with mild-to-severe diabetes-related ED were randomized to receive either placebo or Cialis at doses of up to 20 mg for 12 weeks. Results indicated 64 percent of men taking Cialis 20 mg reported improved erections, compared with 25 percent for placebo. Treatment with Cialis significantly improved sexual function compared with placebo across all primary and secondary study endpoints, regardless of patient age, duration and severity of ED, or diabetes.

Importantly, study participants reflected a broad cross section of men with diabetes and included those with poor glucose control, diabetic retinopathy (damage to the retina in the eyes) and diabetic kidney disease. Despite including men with these diabetes-related complications, few side effects were reported in this study. Headache and dyspepsia (indigestion) were the only side effects reported by greater than five percent of study participants. Researchers observed no significant changes in clinical laboratory values, ECGs (electrocardiograms) or blood pressure in this trial. In addition, Cialis(TM) use was not associated with disturbances in color vision for men in the study, including those with diabetic retinopathy. Of the side effects that were reported, the majority were mild to moderate and appeared to diminish with continued treatment. Few patients discontinued treatment due to side effects.

Additional results from the Cialis global Phase III program will be presented at scientific meetings later this year.

Phase II: Up to 88 percent of men with ED of varying etiologies reported improvement

Findings from a Cialis Phase II study are also to be presented at the EAU meeting. In this study, a broad population of ED sufferers of varying severity and causes (including men with diabetes) took Cialis on demand at doses of up to 25 mg for eight weeks. Results indicated that up to 88 percent of men taking Cialis reported significantly improved erections, compared with 28 percent of those taking placebo. Headache and dyspepsia were the only side effects reported by greater than five percent of all Cialis-treated study participants.

Several measures of sexual function and satisfaction indicate Cialis superior to placebo

Men participating in both studies completed the International Index of Erectile Function, a standard sexual function questionnaire used by urologists, which includes questions on a man`s ability to achieve and maintain an erection. To evaluate Cialis` effect versus placebo, researchers compared baseline scores with scores reported after treatment. Additionally, men and their partners completed sexual encounter profile diaries, indicating their perceptions on the success and satisfaction of each sexual attempt. Data reported to date from Phase II and Phase III studies show treatment with Cialis significantly increased the number of successful and satisfying intercourse attempts reported by both men and their partners, relative to placebo. Cialis was well tolerated, and there were no treatment-related serious adverse events.

ED is a common complication in men with diabetes


It is estimated that 150 million adults worldwide have diabetes(1). Experts suggest that between 25 percent and 75 percent of men with diabetes also have ED. Diabetes can cause vascular complications which, in addition to ED, can lead to blindness, kidney failure, heart disease and nerve damage.

According to a recently published study in the British Journal of Urology, ED is a highly prevalent condition that affects an estimated 152 million men worldwide(2). This includes an estimated 90 million men combined in Brazil, France, Germany, Italy, Japan, Spain, the United Kingdom and the United States(3). The disorder is associated with a range of behavioral risk factors, such as cigarette smoking and excessive alcohol consumption, as well as numerous other medical conditions, notably diabetes and cardiovascular disease.

As a result of these often age-related co-morbidities, there is a higher prevalence of ED in older men. In men between the ages of 40 and 70 years, for example, the incidence of severe ED triples from 5 percent to 15 percent, while the probability of moderate ED doubles from 17 percent to 34 percent.

About Lilly ICOS


Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq:ICOS) and Eli Lilly and Company (NYSE:LLY), is developing Cialis(TM), which is currently under investigation for the treatment of both male erectile dysfunction and female sexual dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS, located in Bothell, Wash., combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. ICOS` disease targets include erectile dysfunction, female sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases.

This press release contains forward-looking statements about the potential of the investigational compound Cialis (IC351) in treating male erectile dysfunction that reflect management`s current beliefs. However, as with any pharmaceutical under development, there are risks and uncertainties in the process of development and regulatory review. There are no guarantees that future clinical trials will confirm the preliminary results reported in this release or that the product will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see the U.S. Securities and Exchange Commission filings of ICOS and Lilly.

(1) International Diabetes Federation website.


(2) Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-56.

(3) Decision Resources, Inc., Erectile Dysfunction. Pharmacor Mosaic Service, 2000

CONTACT: Lilly
Jeffrey Newton, 317/276-3570
or
ICOS
Lacy Fitzpatrick, 425/415-2207

[Alibabus]

@wunram
ich würde mich freuen, wenn du mal das wichtigste daraus übersetzen könntest
icos hält sich auch in dieser börsenphase relativ stabil!, soviel steht fest, aber ist das nun gut oder sehen wir irgendwann mal einen übertriebenen absturz?
Alibabus

[Wunram]

@Alibus

eigentlich sollte man ja schon die Sprache des Unternehmens könne, bei dem man investiert ist, wie kann man sonst irgendwelche Bilanzen oder news verstehen??

trotzdem:

Cialis

Medikament gegen diabetisbedingte Erektionsstörungen; Diabatis hat negativen Einfluss auf Nerven und Blutgefäße

- die erste Phase III Studie ist abgeschlossen; bei 64% der 216 Probanden mit leichten bis schweren diabetisbedingten Erektionsstörungen konnten durch Cialisgaben von 20 mg täglich eine verbesserte Erektion festgestellt werden (was immer das auch bedeuten mag) Von den Testpersonen die einen Placebo erhielten hatten 25% Verbesserungen zu verzeichnen (da sieht man(n) es mal wieder, der Glaube hilft auch)

Nebenwirkungen zeigen sich bei etwa 5% der Probanden lediglich durch Kopfschmerzen und dyspepsia (weis ich grad auch nicht was das auf deutsch heißt)

(jetz kommen noch ein paar interessante Werte zu Markt)

Weltweit gibt es 150 Millionen Erwachsenen mit Diabetis. Bei den Männern geht man von einem Anteil von 25-75% aus, die dadurch Erektionsstörungen haben.

Eine weiter Studie berichtet von 152 Millionen Männern weltweit die Erektionsstörungen haben. Davon ca. 90 Millionen in Brasilien, Frankreich, Deutschland, Italien, Japan Spanien, England und USA.......

also ein großer Absatzmarkt- weil gep....ert wird immer.

Wunram

[Wunram]

@Alibus

eigentlich sollte man ja schon die Sprache des Unternehmens könne, bei dem man investiert ist, wie kann man sonst irgendwelche Bilanzen oder news verstehen??

trotzdem:

Cialis

Medikament gegen diabetisbedingte Erektionsstörungen; Diabatis hat negativen Einfluss auf Nerven und Blutgefäße

- die erste Phase III Studie ist abgeschlossen; bei 64% der 216 Probanden mit leichten bis schweren diabetisbedingten Erektionsstörungen konnten durch Cialisgaben von 20 mg täglich eine verbesserte Erektion festgestellt werden (was immer das auch bedeuten mag) Von den Testpersonen die einen Placebo erhielten hatten 25% Verbesserungen zu verzeichnen (da sieht man(n) es mal wieder, der Glaube hilft auch)

Nebenwirkungen zeigen sich bei etwa 5% der Probanden lediglich durch Kopfschmerzen und dyspepsia (weis ich grad auch nicht was das auf deutsch heißt)

(jetz kommen noch ein paar interessante Werte zu Markt)

Weltweit gibt es 150 Millionen Erwachsenen mit Diabetis. Bei den Männern geht man von einem Anteil von 25-75% aus, die dadurch Erektionsstörungen haben.

Eine weiter Studie berichtet von 152 Millionen Männern weltweit die Erektionsstörungen haben. Davon ca. 90 Millionen in Brasilien, Frankreich, Deutschland, Italien, Japan Spanien, England und USA.......

also ein großer Absatzmarkt- weil gep....ert wird immer.

Wunram

[Wunram]

ich wollts wirklich nur einmal losschicken

Sch... Maus

Gruß
Wunram

[Wunram]

bald Zahlen....


ICOS Announces Financial Results and Conference Call On April 26

BOTHELL, Wash.--(BUSINESS WIRE)--April 16, 2001--ICOS Corporation (Nasdaq:ICOS) will announce its first quarter financial results as scheduled on April 26, 2001 after the market closes. Company management will host a conference call at 1:30 p.m. PDT (4:30 p.m. EDT) following the announcement.

The conference call, with reservation number 17262451, can be accessed live by phone at 1:30 p.m. PDT at 415/908-6285 or in a replay for 24 hours at 800/633-8284 from within the U.S. or 858/812-6440 from outside the U.S. Additionally, a webcast is available live and archived until April 30, by going to ICOS` website at www.icos.com. For additional information on ICOS, including previous press releases, see www.icos.com on the Internet.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. These target areas include erectile dysfunction, female sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases.

http://www.businesswire.com/cnn/icos.shtml


CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207

[Wunram]

und da sind sie -0,29$ consensus war -0,36$!!

und beginn der phase III Erprobung mit Pafase(R) (rPAF-AH) an 2.500 probanden

ICOS Reports Results for First Quarter of 2001

BOTHELL, Wash.--(BUSINESS WIRE)--April 26, 2001--ICOS Corporation (Nasdaq:ICOS) (the "Company") today released its financial results for the first quarter ended March 31, 2001, and summarized progress on its lead product candidates.

Since the beginning of the year the Company and its joint venture partners have advanced the development of two lead product candidates, Cialis(TM) and Pafase(R). At the European Urological Association held in April, the first Phase 3 results were presented on Cialis, a new PDE5 inhibitor being developed by Lilly ICOS LLC ("Lilly ICOS") for the treatment of erectile dysfunction. Professor Inigo Saenz de Tejada, of the Foundation for Research and Development in Andrology in Madrid, Spain, discussed the strong results in a particularly difficult to treat population, men with diabetes-related erectile dysfunction. Additional results from the Cialis Phase 3 program will be presented at scientific meetings later this year.

Separately, patient enrollment has begun in a pivotal Phase 3 trial with the Pafase (rPAF-AH) product candidate, being jointly developed by ICOS and Suntory Limited of Japan. This follows the successful completion of a Phase 2 trial in patients with severe sepsis and multiple traumatic injuries that was reported in 2000.

For the first quarter of 2001, ICOS reported a net loss of $15.2 million ($0.29 per share), compared to a net loss of $67.5 million ($1.49 per share) for the first quarter of 2000. Results for the first quarter of 2000 include a $63.1 million charge ($1.39 per share) for the cumulative effect on prior years of adopting Securities and Exchange Commission Staff Accounting Bulletin No. 101, as amended ("SAB 101"), "Revenue Recognition in Financial Statements," effective Jan. 1, 2000.

Total revenue was $18.9 million for the first quarter of 2001, compared to $17.2 million for the first quarter of 2000. First quarter 2001 cost reimbursement revenue from collaborative research and development activities increased $1.9 million, to $11.7 million, compared to $9.8 million in the prior year. The increase is primarily due to revenue from ICOS-Texas Biotechnology L.P., which was formed in June 2000 to develop and commercialize endothelin receptor antagonists, such as sitaxsentan and TBC3711. For the quarters ended March 31, 2001 and 2000, the Company recognized as revenue $6.6 million and $7.4 million, respectively, of the $63.1 million of deferred revenue that was recorded upon adoption of SAB 101.

Total operating expenses were $24.5 million in the first quarter of 2001, compared to $21.8 million in the 2000 first quarter. Research and development expense increased $2.7 million, compared to the 2000 quarter, to $23.0 million in 2001. The increase in research and development expense reflects the progression of development activities for Pafase, sitaxsentan, TBC3711 and small molecule product candidates IC485 and IC747, partially offset by costs in the prior year associated with clinical programs that were discontinued later in 2000.

In the first quarter of 2001, the Company recognized $13.0 million of losses related to its equity interests in affiliates, compared to $1.5 million of affiliate losses in the first quarter of 2000. The increase primarily reflects the Company`s share of operating losses of Lilly ICOS. In the third quarter of 2000, the Company began recognizing its share of Lilly ICOS` losses because it became responsible for funding a proportionate share of Lilly ICOS operations. Previously, Eli Lilly and Company funded 100% of Lilly ICOS` operations.

At March 31, 2001, the Company had cash, cash equivalents, investment securities available for sale and interest receivable of $216.2 million.

The Company`s results of operations will vary significantly from quarter to quarter. Results will depend on, among other factors, the timing of revenue and expenses, the establishment of collaborative research agreements, and the progress of the Company`s research and development efforts, including the achievement of milestones under new and existing licensing and collaborative agreements.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. The Company has advanced clinical trials in erectile dysfunction, severe sepsis and pulmonary arterial hypertension.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the Company`s results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company`s latest Annual Report on Form 10-K and its other public filings filed with the Securities and Exchange Commission.

ICOS Corporation
SELECTED FINANCIAL DATA
(in thousands, except per share data)

Three months ended
March 31,
-----------------------
2001 2000
---------- ----------
Statement of Operations Data:

Revenue:
Collaborative research and
development from related parties $ 11,726 $ 9,777
Licenses of technology to related parties 6,614 7,423
Other 560 -
---------- ----------
Total revenue 18,900 17,200

Operating expenses:
Research and development 23,025 20,277
General and administrative 1,487 1,492
---------- ----------
Total operating expenses 24,512 21,769
---------- ----------
Operating loss (5,612) (4,569)
Other income (expense):
Equity in losses of affiliates (12,993) (1,483)
Investment income 3,163 1,141
Other, net 289 462
---------- ----------
Loss before cumulative effect of change in
accounting principle (15,153) (4,449)
Cumulative effect of change in
accounting principle - (63,075)
---------- ----------
Net loss $ (15,153) $ (67,524)
========== ==========

Loss per common share - basic and diluted:
Loss before cumulative effect
of change in accounting principle ($0.29) ($0.10)
Cumulative effect of change
in accounting principle - ($1.39)
Net loss ($0.29) ($1.49)

Weighted average common shares
outstanding - basic and diluted 52,531 45,169


Balance Sheet Data: March 31, Dec. 31,
2001 2000
---------- ----------

Cash, cash equivalents, investment
securities and interest receivable $ 216,218 $ 229,400
Receivables from related parties under
collaborative arrangements 24,357 17,051
Net property and equipment 18,729 19,127
Other 2,928 2,596
---------- ----------
Total assets $ 262,232 $ 268,174
========== ==========

Due to affiliates $ 37,580 $ 25,053
Other current liabilities 11,142 11,880
Deferred research and development revenue
from related parties 13,532 20,146
Stockholders` equity 199,978 211,095
---------- ----------
Total liabilities and stockholders` equity $ 262,232 $ 268,174
========== ==========

CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207
http://www.businesswire.com/cnn/icos.shtml

[Kelbi]

Kleine Info am Rande:

ICOS schliesst heute auf 61,85 USD, neues ATH wenn mich nicht alles täuscht und auch noch Ausbruch aus einem aufsteigenden Dreieck, gebildet seit 03/2000 Frage an die Techniker, was sagt ihr dazu?

Gute Nacht

Kelbi

[JakeBl.]

Mit der Aktie werden wir noch alle viel Freude haben ;-). Das ATH wird gehalten, bzw. stetig gehalten. Sollten in der nächsten Zeit nochmals gute News kommen, halte ich für die nächsten 3 Monate ein Kurzziel von ca. 90,00 Euro für realistisch - und das soll natürlich noch nicht das Ende sein.

Gruss

JakeBl.

[Wunram]

mal wieder ein neuer Test

ICOS Corporation and Texas Biotechnology Corporation Initiate a Pivotal Trial in Pulmonary Arterial Hypertension

HOUSTON and BOTHELL, Wash.--(BUSINESS WIRE)--May 30, 2001-- ICOS-Texas Biotechnology, L.P., a partnership formed by ICOS Corporation (Nasdaq:ICOS) and Texas Biotechnology Corporation (AMEX:TXB), announced that patients are being recruited for the STRIDE (Sitaxsentan To Relieve ImpaireD Exercise in pulmonary hypertension) Trial, a pivotal Phase 2/3 study with sitaxsentan, an oral endothelin A receptor antagonist.

The objective of this randomized, double-blind, placebo-controlled trial is to demonstrate the safety and efficacy of sitaxsentan as a new once a day treatment for patients with pulmonary arterial hypertension. The primary endpoint is change in exercise capacity over the 12-week study period. The study also will evaluate changes in 6-minute walk distance, cardiopulmonary hemodynamics, and quality of life as secondary endpoints. This North American trial is designed to enroll approximately 180 patients. A Data Safety Monitoring Board will review safety results on an ongoing basis during the study.

Dr. Robyn J. Barst, Professor of Pediatrics, Director of New York Presbyterian Hospital Pulmonary Hypertension Center/Columbia University and Chair of the STRIDE Scientific Advisory Board stated, "Interest in selective endothelin A antagonists for pulmonary arterial hypertension is supported by data presented on sitaxsentan at last year`s American Heart Association meeting. These data support the belief that endothelin A receptor antagonists may represent a new class of drugs to treat pulmonary arterial hypertension." Dr. Barst was one of two investigators in an open-label pulmonary arterial hypertension trial for sitaxsentan.

Pulmonary arterial hypertension is a progressive and potentially life-threatening disease that is estimated to afflict approximately 100,000 patients worldwide. It is characterized by increased pulmonary artery pressure, leading to heart failure and death. Endothelin, a potent vasoconstrictive substance, exerts its effects through activation of endothelin A and B receptors. The endothelin A receptor is involved in vasoconstriction and is believed to contribute to increased pulmonary artery pressures while the endothelin B receptor is involved in vasodilatation and endothelin clearance. The compounds in the ICOS-Texas Biotechnology partnership are highly selective endothelin A receptor antagonists.

Texas Biotechnology, a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for its expertise in small molecule drug development and vascular biology. Argatroban, its first FDA-approved product, is being marketed by GlaxoSmithKline for heparin-induced thrombocytopenia. Additional studies are seeking to broaden this initial indication for Argatroban in ischemic stroke, angioplasty and hemodialysis. Texas Biotechnology has several other products in clinical development for pulmonary arterial hypertension, essential hypertension, congestive heart failure and asthma.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry, and genomics to develop highly innovative products with significant commercial potential. ICOS applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. ICOS has advanced clinical trials in sexual dysfunction, severe sepsis, and pulmonary arterial hypertension.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the Companies` results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Companies` latest Annual Reports on Form 10-K and its other public filings filed with the Securities and Exchange Commission.

CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207
http://www.businesswire.com/cnn/icos.shtml

or
Texas Biotechnology Corporation
Pam Murphy, 713/796-8822

[thomas97]

wer hat das neue potenzmittel uprima auf den markt gebracht?
ist es von icos?was ist mit cialis wann kommt es endlich auf den markt?

[Wunram]

erst noch ein paar positive tests

In a New Phase 3 Study, Cialis -IC351- 20 Mg Improved Erections in 85 Percent of Men With Erectile Dysfunction, Regardless of Severity
SEATTLE--(BUSINESS WIRE)--June 1, 2001--


Additional Studies Provide Data on 24-Hour Responsiveness and Time to Onset

Results of a new Phase 3 placebo-controlled study of Cialis(TM), (IC351), a new PDE5 inhibitor in development by Lilly ICOS LLC to treat erectile dysfunction (ED), show that 85 percent of men taking Cialis 20 mg reported improved erections. Further, in two additional clinical trials, men reported improved ability to achieve erections up to 24 hours after taking the drug. These data are being presented for the first time during the 96th Annual Meeting of the American Urological Association here.

"We are especially pleased by the results of this study, considering that Cialis demonstrated benefit in men with all degrees of ED, including those with severe cases," said Dr. Gerald Brock, of St. Joseph`s Health Centre, Department of Urology, Ontario, Canada. "Based on a collective review of the data presented today, the good response rate, duration, and tolerability of Cialis give it the potential to become a valuable treatment option for men with ED and their partners." Cialis significantly improved erections in men with mild-to-severe ED

The Phase 3 study examined the safety and efficacy of "on-demand" Cialis treatment in 196 men suffering from mild-to-severe ED. Men in the study were randomized to receive up to 20 mg of Cialis or placebo over a 12-week period. Men were free to take their study medication without restrictions on food or alcohol consumption and to have sex with their partners at the time of their choosing after each dose.

In the study, 85 percent of men taking Cialis 20 mg reported significantly improved erections compared with baseline. In addition, 78 percent of intercourse attempts recorded by all men on Cialis 20 mg were successful. Importantly, 63 percent of men with ED treated with Cialis 20 mg achieved an erectile function score experts consider "normal" for healthy men as measured by the International Index of Erectile Function (IIEF).

On the 10 mg dose, 92 percent of men reported improved erections, and 70 percent of intercourse attempts were successful. Forty-two percent of men taking the 10 mg dose achieved IIEF scores in the normal range. Fifty-four percent of patients on placebo in the study reported improved erections, while 43 percent of their attempts were successful. Twenty percent of men taking placebo attained IIEF scores in the "normal" range.

In this study, side effects were mild to moderate, and their incidence diminished with continued treatment. The most commonly reported side effects were backaches, muscle aches and upset stomach. There were no clinically significant changes in blood pressure, heart rate, electrocardiograms or laboratory tests attributable to treatment with Cialis. Cialis extended duration of responsiveness and onset data

In the first of two clinical trials also presented at the AUA meeting, 61 men with mild-to-severe ED were randomized to receive Cialis (IC351) 10 mg or placebo. After taking Cialis, the men were evaluated by RigiScan(TM) (a device for measuring the firmness and duration of erections) during exposure to visual sexual stimulation. Men in the Cialis group were significantly more successful in achieving erections than men in the placebo group at 24 hours postdose.

In the second trial to measure the onset of responsiveness, 223 men received Cialis up to 20 mg or placebo in a home-based study. The men were instructed to take the medication immediately before engaging in sexual activity and to use a stopwatch to record the elapsed time until they achieved an erection sufficient for successful intercourse. In this trial, the ability to achieve an erection after sexual stimulation was statistically superior in the group taking Cialis 20 mg compared with the placebo group at 16 minutes postdosing. Men taking Cialis 20 mg in this study also recorded statistically greater success at second sexual encounters than men on placebo for a period of up to 24 hours.

In these studies on duration of responsiveness, there were no serious side effects. The most common side effect reported was headache. Duration of responsiveness important to men with ED

Duration of responsiveness following dosing is an important attribute, according to 88 percent of respondents in a recent Harris Interactive survey of 256 men with erectile dysfunction in the U.S. The men who participated in the survey indicated the duration of responsiveness was either "very important" or "extremely important" in selecting a treatment.

Erectile dysfunction is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. It affects an estimated 152 million men and their partners worldwide with many cases caused by physical conditions, including cardiovascular disease and diabetes. About Lilly ICOS

Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq: ICOS) and Eli Lilly and Company (NYSE:LLY), is developing Cialis, which is currently under investigation for the treatment of sexual dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS, located in Bothell, Wash., combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. ICOS` disease targets include sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases.

This press release contains forward-looking statements about the potential of the investigational compound Cialis(TM) (IC351) in treating male erectile dysfunction that reflect management`s current beliefs. However, as with any pharmaceutical under development, there are risks and uncertainties in the process of development and regulatory review. There are no guarantees that future clinical trials will confirm the preliminary results reported in this release or that the product will receive regulatory approvals or prove to be commercially successful. In addition, new pharmaceutical products can face risks of intellectual property claims and product litigation. For further discussion of these and other risks and uncertainties, see the U.S. Securities and Exchange Commission filings of ICOS and Lilly.

CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207
or
Eli Lilly and Company
Blair Austin, 317/277-6738

[Wunram]

Statement to the Media -- European Patent Office Says Pfizer`s Method of Use Patent for ED Invalid

BOTHELL, Wash.--(BUSINESS WIRE)--July 18, 2001--Lilly ICOS LLC today announced that the Opposition Division of the European Patent Office (EPO) declared invalid Pfizer`s "method of use" patent EP702555 for PDE inhibitors, including sildenafil. The ruling was made following a three-day hearing by the Opposition Division. Lilly ICOS offered the following statement regarding the decision:

This decision makes it clear that Pfizer is not entitled to
exclusivity in the field of erectile dysfunction (ED).

Lilly ICOS is pleased, but not surprised, with the decision.
Lilly ICOS was confident -- as were the other companies that
opposed the method of use claims -- that this particular
patent was invalid. This decision is consistent with the
decision of the UK court in November last year, which also
held that the UK designation of the same patent was invalid.

This decision leaves unaffected Pfizer`s compound patent,
which covers sildenafil.


Lilly ICOS recently submitted applications with the US Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMEA) requesting marketing approval of Cialis(TM) (IC351) for the treatment of ED. About Lilly ICOS

Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq:ICOS) and Eli Lilly and Company (NYSE:LLY), is developing Cialis (IC351), which is currently under investigation for the treatment of sexual dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS, located in Bothell, Wash., combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. ICOS` disease targets include sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases.

This contains forward-looking statements about the potential of the investigational compound Cialis (IC351) in treating male erectile dysfunction that reflect management`s current beliefs. However, as with any pharmaceutical under development, there are risks and uncertainties in the process of development and regulatory review. There are no guarantees that future clinical trials will confirm the preliminary results reported in this release or that the product will receive regulatory approvals or prove to be commercially successful. In addition, new pharmaceutical products can face risks of intellectual property claims and product litigation. For further discussion of these and other risks and uncertainties, see the U.S. Securities and Exchange Commission filings of ICOS and Lilly.

CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207
http://www.businesswire.com/cnn/icos.shtml
or
Eli Lilly and Company
Angela Sekston, 317/277-8503

[Wunram]

solch eine Meldung ist also bei uns -5€ oder -7,4% Wert - auf was soll man eigentlich noch reagieren?

7/24/2001

10 keepers from the bargain pile

MSN MoneyCentral
Jim Jubak, columnist for MSN Moneycentral, has selected this stock ( ICOS Anm. Wunram) as one of ten additions to his "Future Fantastic 50 portfolio" after recently dropping ten. He specified three "rules for finding the gold in the garbage." One of the rules to "find the gold" is for investors to "look for companies that are investing in cutting costs during this downturn." He says that one should also take a look at "companies that continue to move full-steam-ahead on product development even while sales are soft." Lastly, he added firms that "own an expensive-to-match asset," which helps shelter them from the ultra-competitive landscape.

[okujawa]

Ist recht ruhig um Icos geworden.
Hat einer eine gute Idee wie es weiter geht ?
cu ok

[Wunram]

so gehts weiter!!!
FDA Accepts Cialis NDA

BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 31, 2001--ICOS Corporation (Nasdaq:ICOS) announced today that the New Drug Application (NDA) for Cialis(TM) has been accepted for review by the U.S. Food and Drug Administration. "Even though it was stated in our last quarterly conference call, that we probably would not make an announcement, several of our shareholders have made inquiries and therefore, we decided to make this release," stated Lacy Fitzpatrick, Associate Director of Investor Relations.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. These target areas include erectile dysfunction, sepsis, psoriasis, pulmonary hypertension and other cardiovascular diseases.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the Company`s results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company`s latest Annual Report on Form 10-K and its other public filings filed with the Securities and Exchange Commission.

http://www.businesswire.com/cnn/icos.shtml


CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207

[Wunram]

hat zunächst eine beeindruckende wirkung auf den intraday-chart:

[Wunram]

jetzt gehen die amis wieder ihren hotdog essen - und mit fast allen anderen werten gehts wieder etwas nach unten;

aber der chart zeigt die weitere richtung:

[okujawa]

hat keiner mehr was zu Icos zu sagen oder hat es allen die Sprache verschlagen ?
Der aktuelle Kurs ist ja mehr als besch***.
cu
ok

[Wunram]

@okujawa

der Kurs hat sich doch eigentlich ganz gut gehalten - siehe chart unten.

Was ist eigentlich aus der Bear Stearns Health Care Conference vom 13. September geworden bei der CEO Clark sprechen wollte. Ich vermute, die ist wegen der Ereignisse asugefallen.

Wollen mal sehen, wie die Entwicklung weitergeht. Die Pipeline klinische Erprobung:

Cialis________FDA Zulassung beantragt,
Pafase________Phase III,
Sitaxsentan____Phase IIb/III,
IC351_________Phase II sehr interessant -das Gegenstück zu Cialis
TBC3711_______Phase I
IC14__________Phase I
IC747_________Phase I

Cialis soll meines Wissens im 4. Quartal auf den Markt kommen. Dann gehts wieder aufwärts.

Wunram

[Wunram]

news

First Presentation of Large-Scale Integrated Analysis of Phase III Data on Cialis --Tadalafil-- Shows Consistent Effect in Men With Erectile Dysfunction

ROME, Italy--(BUSINESS WIRE)--Oct. 2, 2001--

New study shows Cialis absorption not affected by food intake

The first presentation of a large-scale integrated analysis of Phase III data on Cialis(TM) (tadalafil), a new oral treatment for erectile dysfunction (ED) being developed by Lilly ICOS LLC, shows a consistent response to the investigational treatment. Eighty-one percent of patients treated with 20 mg Cialis (N=165) reported improved erections.(1) This analysis, taken from studies of 972 men with ED (711 Cialis, 261 placebo), and other new research-- including a study that shows Cialis` absorption was not decreased by food intake(2)-- were presented today at the 4th Congress of the European Society for Sexual and Impotence Research (ESSIR) in Rome.

"With each new data analysis, we continue to see consistent and robust scientific evidence that Cialis has an attractive profile," said Charles Beasley, M.D., medical director, Eli Lilly and Company. "The many findings from these Phase III analyses suggest Cialis has the potential to be a valuable treatment for a large number of men who have ED, regardless of severity. Cialis has other attributes that may also be clinically important."

Pharmacokinetic Analyses: Key Findings

Several studies were conducted to evaluate Cialis absorption by the body. Pharmacokinetic studies are important because they can identify differences in drug absorption and elimination in the body between various patient populations. These studies investigated, among other characteristics, the impact of age, diabetes, renal function, and liver function on the pharmacokinetics of Cialis. There were no clinically significant differences in extent of drug exposure among these diverse groups. In addition, Cialis` absorption was not decreased by food intake.(3)

"These findings suggest that dosing for Cialis should be simple and uncomplicated, which is important from a health care professional standpoint," said Harmut Porst, associate professor of the urological department of the medical university in Bonn, Germany, and secretary general of the ESSIR. "From a patient`s point of view, it is the absence of food effect that I find most interesting. These data suggest that a man can have a normal, romantic dinner with his partner without diminishing the effect of Cialis."

Integrated Phase III Analysis - Key Findings From General and Diabetes Populations

The integrated Phase III analysis included randomized, placebo-controlled studies involving 972 men with ED of various causes and severity. Men were treated with Cialis (ranging up to 20 mg) or placebo for 12 weeks. Improved erections, as assessed by the Global Assessment Questionnaire (GAQ), were reported by 81 percent of patients taking 20 mg Cialis (35 percent placebo).(4)

The Phase III integrated analysis showed Cialis improved erections in 76 percent of the subset of men with diabetes taking a 20 mg dose(5). Diabetes-related ED is often more difficult to treat than ED caused by other factors. ED is a common complication of diabetes, affecting between 27 and 75 percent of men with the disease.(6) The World Health Organization estimates 151 million people worldwide have diabetes.(7)

In the Phase III studies, participants were instructed to take study medication at the time of their choosing prior to sexual activity, with no more than one dose daily. No instructions were given with regard to food or alcohol consumption and time of dosing.

Cialis Period of Responsiveness - Key Findings

Two separate studies, presented in Europe for the first time, showed Cialis works for up to 24 hours and as early as 16 minutes after taking the pill(8). In the first study, 61 men with mild-to-severe ED were randomized to take Cialis or placebo and underwent RigiScan(R) (device for measuring firmness and duration of erections) evaluations during exposure to visual sexual stimulation. Men taking Cialis experienced significantly more success in improvement of erectile function than men in the placebo group, even when evaluated 24 hours after dosing. In the second study, designed to measure the drug`s onset, 223 men took Cialis or placebo and used a stopwatch to record the elapsed time until they achieved an erection sufficient for intercourse. The ability to achieve an erection (with sexual stimulation) was statistically superior in the group taking Cialis 20 mg, compared with the placebo group, at 16 minutes after dosing, and the majority of men taking Cialis were able to respond within 30 minutes.

"This period of responsiveness may be an important attribute for emerging ED treatments, as it may enable a man and his partner to have sex whenever they choose within a 24-hour period," Professor Porst said.

Side Effects

Throughout the Phase III trials, Cialis was well tolerated, with generally mild-to-moderate side effects that diminished in frequency with continued treatment. The most commonly reported side effects throughout the Phase III trials were headache, upset stomach, backache, muscle aches, flushing and nasal congestion. The discontinuation rate due to side effects in these trials was comparable to that with placebo.

Cialis is currently under review for marketing approval by the European Agency for the Evaluation of Medicinal Products (EMEA) and the US Food and Drug Administration (FDA).

Erectile dysfunction is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. It affects an estimated 152 million men worldwide with many cases caused by physical conditions, including cardiovascular disease and diabetes.(9) In Europe, approximately 31 million men suffer from ED.(10)

About Lilly ICOS

Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq: ICOS) and Eli Lilly and Company (NYSE:LLY), is developing Cialis, which is currently under investigation for the treatment of sexual dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers-- through medicines and information-- for some of the world`s most urgent medical needs.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. ICOS applies its integrated approach to specific target areas where it has expertise. ICOS believes its strategy of targeting multiple therapeutic areas by developing drugs that act through distinct molecular mechanisms increases its chances of successfully developing commercial products.

This press release contains forward-looking statements about the potential of the investigational compound Cialis in treating male erectile dysfunction that reflect management`s current beliefs. However, as with any pharmaceutical under development, there are risks and uncertainties in the process of development and regulatory review. There are no guarantees that future clinical trials will confirm the preliminary results reported in this release or that the product will receive regulatory approvals or prove to be commercially successful. --------------------------- 1 Symposium, "Expanding treatment options for male impotence." 4th Congress of the European Society for Sexual and Impotence Research. October 2, 2001. 2 Patterson, B et al. "The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351)." Poster presentation at the 4th Congress of the European Society for Sexual and Impotence Research. Poster presented 08.00-09.00 October 3, 2001. 3 Ibid. 4 CME symposium, "Expanding treatment options for male impotence." 4th Congress of the European Society for Sexual and Impotence Research. October 2, 2001. 5 Ibid. 6 Guay A. Treatment of erection dysfunction in men with diabetes. Diabetes Spectrum 1998; 11: 2 7 International Diabetes Federation. Diabetes Atlas 2000. 8 Padma-Nathan, H. "Tadalafil (IC351) provides prompt response and extended period of responsiveness for the treatment of men with ED." Poster presentation at the 4th Congress of the European Society for Sexual and Impotence Research. Poster presented 08.00-09.00 October 1, 2001. 9 Aytac et al. The Likely Worldwide Increase in Erectile Dysfunction Between 1995 and 2025 and Some Possible Policy Consequences. BJU International. 1999; 84:50-56. 10 Ibid.

http://www.businesswire.com/cnn/icos.shtml

--30--NTC/se*

CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207
or
Eli Lilly & Company
Blair Austin, 317/277-6738

© 2001 ICOS

[Wunram]

news

ICOS Scheduled at UBS Warburg Global Life Science Conference

BOTHELL, Wash., Oct 5, 2001 (BUSINESS WIRE) -- ICOS Corporation (Nasdaq:ICOS) announced today that Paul Clark, ICOS Chairman and CEO, will speak at the UBS Warburg Global Life Science Conference on October 12, 2001 at 10:00 a.m. EDT. The conference is being held at The Pierre Hotel in New York, New York.
The presentation can be heard in real-time and as a replay (for 48 hours). The call in numbers will be: Real-time: [phone] (U.S.) / [phone] (international) Replay: [phone] (U.S.) / [phone] (international)

Additional information on ICOS, including press releases, can be accessed on the ICOS website, www.icos.com.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. ICOS applies an integrated approach to specific target areas where we have expertise, including erectile dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases, inflammatory diseases and cancer.


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the Company`s results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company`s latest Annual Report on Form 10-K and its other public filings filed with the Securities and Exchange Commission.


CONTACT:
ICOS Corporation
Lacy Fitzpatrick, 425/415-2207

[Wunram]

Guten Morgen,

Ergebnis 3Q: -$0,45 pro Aktie.
Erwartet waren: -$0,56 pro Aktie. geht ja oder???

ZahlenICOS Reports Results for Third Quarter of 2001

BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 24, 2001--ICOS Corporation (Nasdaq:ICOS). (the "Company" or "ICOS") today summarized recent events and released financial results for the third quarter ended September 30, 2001.

During the year, ICOS and Eli Lilly and Company ("Eli Lilly") completed registrational Phase 3 trials with Cialis(TM) and, on August 31, 2001, Lilly ICOS LLC ("Lilly ICOS") announced that the Cialis(TM) New Drug Application ("NDA") had been accepted for review by the U.S. Food and Drug Administration ("FDA"). Regulatory submissions have also been filed with other agencies outside of the U.S., including the European Agency for the Evaluation of Medicinal Products.

On October 2, 2001, the Company and Eli Lilly presented a large-scale integrated analysis of Phase 3 data on Cialis(TM) at the European Society for Sexual Impotence Research in Rome. Clinical results indicated that Cialis(TM) is effective in improving patients` ability to engage in sexual intercourse, as eighty-one percent of clinical study patients treated with 20 mg of Cialis(TM) reported improved sexual function. Based on the results of pharmacokinetic analyses, medical experts also concluded that food intake did not decrease the body`s ability to absorb Cialis(TM) and that the impact of age, diabetes, and renal and liver function showed no clinically significant differences in the extent of drug exposure among these diverse groups. Throughout the Phase 3 clinical trials, Cialis(TM) has shown to be well tolerated, with generally mild-to-moderate side effects that have diminished in frequency with continued treatment.

The Company previously reported the results of two separate Cialis(TM) studies regarding period of responsiveness. These studies indicated that Cialis(TM) works as early as 16 minutes after taking the pill and for up to 24 hours.

Clinical progress during the third quarter of 2001 included patient enrollments in the pivotal Pafase(R) Phase 3 clinical trial for severe sepsis, the Phase 2/3 clinical trial with sitaxsentan for pulmonary arterial hypertension and the Phase 1 clinical trial with IC747, an LFA-1 antagonist, for the potential treatment of psoriasis. ICOS continued its positive momentum with the formation of a worldwide collaboration with Biogen, Inc. to develop IC747 and other LFA-1 antagonists.

For the third quarter of 2001, ICOS reported a net loss of $24.4 million ($0.45 per share), compared to a net loss of $11.5 million ($0.25 per share) for the third quarter of 2000.

Total revenue was $18.9 million for the third quarter of 2001, compared to $21.7 million for the third quarter of 2000. Third quarter 2001 cost reimbursement revenue from collaborative research and development activities increased $2.4 million, to $13.9 million, compared to $11.5 million in the prior year. The increase was primarily due to revenue related to the Pafase(R) Phase 3 clinical trial for severe sepsis, the sitaxsentan Phase 2/3 clinical trial for pulmonary arterial hypertension and clinical activities associated with TBC3711. Cost reimbursement revenue from Lilly ICOS decreased in the third quarter of 2001 compared to the third quarter of 2000, as certain clinical activities were completed prior to submission of the Cialis(TM) NDA to the FDA in June 2001. Third quarter 2000 cost reimbursement revenue also included funding, which ended in the 2001 first quarter, from ICOS Clinical Partners, L.P.

Revenue from licenses of technology to related parties was $2.3 million in the third quarter of 2001, compared to $10.2 million in the third quarter of 2000. The decrease was due to the completion of Cialis(TM) development activities required to file the NDA in June 2001.

During the third quarter of 2001, the Company recognized $2.7 million in revenue related to the development and manufacture of third party clinical materials. The Company began offering contract manufacturing services in the fourth quarter of 2000.

Total operating expenses were $28.0 million in the third quarter of 2001, compared to $20.8 million in the 2000 third quarter. Research and development expense increased $6.0 million, to $25.7 million in 2001, due to the progression of development activities for Pafase(R), sitaxsentan and TBC3711, partially offset by reduced Cialis(TM) clinical program costs.

In the third quarter of 2001, the Company recognized $18.4 million of losses related to its equity interests in affiliates, compared to $13.4 million in the third quarter of 2000. The increase primarily reflects the higher operating losses of Suncos Corporation and ICOS-Texas Biotechnology L.P. from the continued progression of development activities for Pafase(R), sitaxsentan and TBC3711.

For the nine months ended September 30, 2001, ICOS reported a net loss of $44.8 million ($0.84 per share), compared to a net loss of $87.3 million ($1.90 per share) for the nine months ended September 30, 2000. During the first nine months of 2001, the Company recognized $44.9 million of losses related to its equity interests in affiliates, compared to $18.9 million of affiliate losses for the nine months ended September 30, 2000. The increase in affiliate losses is primarily because the Company became responsible for funding its proportionate share of Lilly ICOS` operations beginning in the third quarter of 2000. Previously, Eli Lilly funded all of Lilly ICOS` operations. Results for the first nine months of 2000 also included a $63.1 million charge ($1.37 per share) for the cumulative effect on prior years of adopting a change in accounting for certain types of revenue.

At September 30, 2001, the Company had cash, cash equivalents, investment securities available for sale and interest receivable of $194.9 million.

The Company`s results of operations may vary significantly from quarter to quarter. Results will depend on, among other factors, the timing of revenue and expenses, the establishment of collaborative research agreements, and the progress of the Company`s research and development efforts, including the achievement of milestones under new and existing licensing and collaborative agreements.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has expertise, including erectile dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases, inflammatory diseases and cancer. ICOS believes the strategy of targeting multiple therapeutic areas by developing drugs that act through distinct molecular mechanisms increases the Company`s chances of successfully developing commercial products.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the Company`s results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company`s latest Annual Report on Form 10-K and its other public filings filed with the Securities and Exchange Commission.

http://www.businesswire.com/cnn/icos.shtml



ICOS Corporation
SELECTED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)

Three months ended Nine months ended
September 30, September 30,
------------------- -------------------
2001 2000 2001 2000
-------- -------- -------- --------

Statement of Operations Data:

Revenue:
Collaborative research
and development from
related parties $ 13,884 $ 11,460 $ 38,009 $ 31,698
Licenses of technology
to related parties 2,294 10,218 29,209 26,822
Other 2,697 -- 4,569 --
-------- -------- -------- --------
Total revenue 18,875 21,678 71,787 58,520
-------- -------- -------- --------

Operating expenses:
Research and development 25,678 19,694 75,421 63,603
General and
administrative 2,289 1,133 5,749 4,253
-------- -------- -------- --------
Total operating
expenses 27,967 20,827 81,170 67,856
-------- -------- -------- --------
Operating income
(loss) (9,092) 851 (9,383) (9,336)

Other income (expense):
Equity in losses of
affiliates (18,437) (13,436) (44,885) (18,922)
Investment income 2,247 918 8,002 3,184
Other, net 914 200 1,478 897
-------- -------- -------- --------
Loss before cumulative
effect of change in
accounting principle (24,368) (11,467) (44,788) (24,177)
Cumulative effect of
change in accounting
principle -- -- -- (63,075)
-------- -------- -------- --------
Net loss $(24,368) $(11,467) $(44,788) $(87,252)
======== ======== ======== ========


Per common share
-- basic and diluted:
Loss before cumulative
effect of change in
accounting principle ($ 0.45) ($ 0.25) ($ 0.84) ($ 0.53)
Cumulative effect of
change in accounting
principle -- -- -- ($ 1.37)
Net loss ($ 0.45) ($ 0.25) ($ 0.84) ($ 1.90)

Weighted average common
shares outstanding
-- basic and diluted 53,715 46,494 53,110 45,851

----------------------------------------------------------------------

Balance Sheet Data: Sept. 30, Dec. 31,
2001 2000
----------------------

Cash, cash equivalents,
investment securities and
interest receivable $194,869 $229,400
Receivables from related parties
under collaborative arrangements 14,327 17,051
Net property and equipment 18,303 19,127
Other 4,714 2,596
-------- --------
Total assets $232,213 $268,174
======== ========

Due to affiliates $ 17,488 $ 25,053
Other current liabilities 13,354 11,880
Deferred research and development
revenue from related parties 14,490 20,146
Stockholders` equity 186,881 211,095
-------- --------
Total liabilities and
stockholders` equity $232,213 $268,174
======== ========



CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207

[Wunram]

Press Releases

ICOS Corporation Announces Pricing of Public Offering of Common Stock

BOTHELL, Wash., Nov 8, 2001 (BUSINESS WIRE) -- ICOS Corporation (Nasdaq:ICOS) (the "Company" or "ICOS") announced today the pricing of its public offering of 5,500,000 shares of common stock at $57.00 per share.
All of the shares are being sold by the Company. The Underwriters have been granted an over-allotment option to purchase an additional 815,789 shares of common stock. Credit Suisse First Boston Corporation and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as joint lead managers for the offering. SG Cowen Securities Corporation, Banc of America Securities LLC and Robertson Stephens, Inc. are acting as co-managers for the offering.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has expertise, including erectile dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases, inflammatory diseases and cancer. ICOS believes the strategy of targeting multiple therapeutic areas by developing drugs that act through distinct molecular mechanisms increases the Company`s chances of successfully developing commercial products.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Copies of the prospectus relating to this offering may be obtained from the Prospectus Department at Credit Suisse First Boston, c/o Prospectus Department, 11 Madison Avenue, New York, New York 10010 and at Merrill Lynch & Co., World Financial Center 5th Fl, North Tower, New York, New York 10281.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS` results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in ICOS` latest Annual Report on Form 10-K and its other public filings filed with the SEC.

http://www.businesswire.com/cnn/icos.shtml" target="_blank" rel="nofollow ugc noopener">http://www.businesswire.com/cnn/icos.shtml

CONTACT: ICOS Corporation
Lacy Fitzpatrick, 425/415-2207

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire. All rights reserved.

[Snoopy28]

Hat jemand neue Infos über den Stand von Cialis???
Die Aktie steht ja nach wie vor Bombenfest im grünen Bereich.

[Snoopy28]

Das dürfte den Anstieg der letzten Tage erklären.

Besonders die zum 24. Dezember geplante Neustrukturierung des Nasdaq-100 Index konnte den BTK gestern beflügeln. 13 Unternehmen, darunter die ehemaligen Technologiegrößen Inktomi, Novell, Ariba (ARBA; 923835) oder CNET Networks, werden durch insgesamt 6 Biotechwerte ersetzt. Zu den glücklichen Unternehmen gehören ImClone Systems (IMCL; 883074), Sepracor (SEPR; 882759), InvitroGen (IVGN; 919313), Cephalon (CEPH; 881752), ICOS (ICOS; 882008) und Protein Design Labs (PDLI; 883428).

[Waschbr]

Hi all,

ich selbst beobachte eine Zeitlang diese Aktie, finde aber, daß trotz aller fundamentals die Charttechnik sehr alarmierende Signale liefert.
Schaut selbst:

http://server92.plusserver.de/forum/showthread.php?

Beachtet bitte meinen letzten Beitrag

Will damit keine Werbung für andere Boards betreiben, sondern Anleger nur auf eventuelle Gefahren hinweisen.

Anmerkung: Bin selber kein professioneller Technicker. Sollten mir grobe Fehler unterlaufen sein, bin ich für konstruktive Kritik sehr dankbar!

Grüße,
Waschbär

[Waschbr]

Sorry, klappt nicht so wie es soll!

Dann halt meinen aktuellsten Beitrag:

Hi all,

Zuerst frohes neues noch mal. Die Party an Neujahr hab ich endlich auch weggesteckt (ach ja, man ist halt nicht mehr ganz so jung).

Ein paar Worte zur Kursentwicklung von Icos (Anmerkung: Jene Biotechfirma, die mit dem Potenzmittel Cialis den Viagra-dominierten Markt aufmischen will).

Wie schon bekannt, hat sich im Monatschart ein Evening Star ausgebildet, welcher als äußerst bearish zu werten ist. Nach den Kurseinbrüchen im September bildete sich im Tageschart ein Island – Reversal aus, welches einen Trendwechsel hätte einläuten können.

Es sah sehr vielversprechend aus, als der primäre Downtrend durchbrochen wurde. Mit Ende dieser Woche hat sich meiner Ansicht nach endgültig gezeigt wo es lang gehen dürfte. Der seit dem Reversal ausgebildete Uptrend wurde durchbrochen.
Viel schwerer dürfte alledings die bearishe Divergenz zwischen Kurs und OBV wiegen. Ich gehe von weiter stark nachgebenden Kursen aus, da der Aktie beständig Kapital entzogen wird (Siehe dabei Wochenchart!!)!


Icos Wochenchart mit OBV würde ich gerne nachliefern, aber irgendwie finde ich keine Möglichkeit mehr Bilder bei Freenet hochzuladen (zumindest solche, die hier sichtbar gemacht werden könnten).

Grüße,
Waschbär

[okujawa]

Hattest Recht, aber sie hält sich ganz gut so um die 60 Euro.
RSI und Stochastik sehen eigentlich ganz gut aus, hoffen wir mal,dass es das war.
cu
ok

[Snoopy28]

Ich hoffe es auch, bald müssten auch wieder Zahlen kommen und davon erwarte ich mir einiges. Vielleicht wäre jetzt echt noch ein guter Zeitpunkt um nachzukaufen.....

[austrobull]

Hallo ICOS Fans !
Ihr wartet wahscheinlich auf Cialis etc. ICOS ist ja gut aber schau euch nur die Bewertung an. Wenn ihr eine Aktie wollen ,die Potential zum 50 Fachen Bewertung in einge Jahren hat, dann schau euch Nastech an (NSTK)
Hat Apomorphin spray gegen ED UND bald komer die ERSTE postitive Meldungen für FSD (Female Sexual Dysfunction: z. doppelt so grosser Markt als für ED). APO für ED soll lizenziert werden jeden Tag jetzt, dann explodiert Nastech
(Market Cap 140 MM USD). Hauptprodkte sind aber naslae Drug-delivery für macro molekylen ( Markt 20 -40 Milliarden).
Der Chance die nur einmal im leben kommt.
Mit freundlichen Grüßen

[okujawa]

Die US-Zulassungsbehörde für Medikamente (FDA) hat das Biotechnologie-Unternehmen Icos und den Pharmakonzern Eli Lilly wegen Verbreitung missverständlicher Produktinformationen verwarnt. Die Unternehmen haben ihre gemeinsam entwickelte Potenzpille Cialis unter anderem in Pressemittelungen als „sicher und effektiv“ gelobt. Der Haken daran ist, dass Cialis bislang noch nicht zugelassen ist - das Recht über die Sicherheit und Tauglichkeit der Pille zu urteilen, liegt allein bei der FDA.

Icos hat daraufhin sofort die betroffenen Texte von seiner Website gelöscht und auch Eli Lilly hat zugesagt, die entsprechenden Materialien zu entfernen. Weiterhin müssen die Unternehmen sich schriftlich zu ihrem Vergehen äußern, um eventuellen Strafen vorzubeugen. Wenn die Firmen sich korrekt verhalten ist nicht mit Komplikationen im Zulassungsprozess zu rechnen: Die Unternehmen hoffen darauf, dass die Potenzpille Cialis im zweiten Halbjahr 2002 die Marktzulassung erhält, um dann Pfizers Viagra Konkurrenz zu machen.

...und es macht sich auch gleich im Kurs bemerkbar -8,6% heftig...!!!
Mit dem Durchbrechen der 50 $ Marke hat Icos garantiert auch Stop/Loss ausgelöst.
cu
ok

[Waschbr]

Hi,

habe mir noch mal die Wochenindikatoren angekuckt.

Sieht alarmierend aus!!
Zunächst im Vergleich zum Amex-Biotechindex hat Icos heute schwach performed.
Was mich aber sehr beunruhigt ist die bearische Divergenz im MACD und vor allem im OBV. Da sieht es geradezu nach Crash aus!!! Kleineren Erholungen schließe ich nicht aus, aber die nächsten Tage und Wochen dürften sehr hart werden.

Anmerkung: Bin nicht in diese Aktie investiert.

Grüße,
Waschbär

[Wunram]

good news

Press Releases
UK Court of Appeal Rules in Lilly ICOS` Favor: Appeals Court Says Pfizer`s Method of Use Patent Invalid

LONDON--(BUSINESS WIRE)--Jan. 23, 2002--Lilly ICOS LLC today announced that the UK Court of Appeal in London upheld a lower court`s ruling that found Pfizer`s entire "method of use" patent for PDE inhibitors to treat erectile dysfunction (ED) was invalid. This decision follows a December 2001 hearing in which Pfizer attempted to reinstate its method of use patent that was struck down by the High Court of Justice in London on November 8, 2000.

Lilly ICOS offered the following statement regarding the decision:

Lilly ICOS is pleased with the Court of Appeal`s decision.
This ruling confirms what we have believed all along--that
Pfizer`s broad method of use patent was invalid.

This decision makes it clear that Pfizer is not entitled to
exclusivity in the field of ED in the UK.

This decision is consistent with the decision of the
Opposition Division of the European Patent Office which ruled
last summer that Pfizer`s method of use patent was invalid.

This decision leaves unaffected Pfizer`s compound patent for
sildenafil.


Lilly ICOS is investigating Cialis(TM) (tadalafil) for the treatment of sexual dysfunction. Requests for marketing approval of Cialis are currently under review by US and European regulatory agencies.

Lilly ICOS LLC is a joint venture between ICOS Corporation (Nasdaq:ICOS) and Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS, located in Bothell, Wash., combines capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and genomics to develop highly innovative products with significant commercial potential. The company applies its integrated approach to specific target areas where it has expertise. ICOS believes this strategy increases the chances of successfully developing commercial products. ICOS` disease targets include sexual dysfunction, sepsis, pulmonary hypertension and other cardiovascular diseases.

This contains forward-looking statements about the potential of the investigational compound Cialis(TM) in treating male erectile dysfunction that reflect management`s current beliefs. However, as with any pharmaceutical under development, there are risks and uncertainties in the process of development and regulatory review. There are no guarantees that future clinical trials will confirm the preliminary results reported in this release or that the product will receive regulatory approvals or prove to be commercially successful. In addition, new pharmaceutical products can face risks of intellectual property claims and product litigation. For further discussion of these and other risks and uncertainties, see the U.S. Securities and Exchange Commission filings of ICOS and Lilly.

--30--brm/se*

CONTACT: Eli Lilly
Angela Sekston, 317/277-8503
or
ICOS Corporation
Lacy Fitzpatrick, 425/415-2207

[reichinrente]

[Wunram]

Zacks All-Star Analyst Issues Recommendations for 6 Stocks: HRC, MRK, IMNX, ICOS, IDBE and SGEN

CHICAGO, Jan. 28 /PRNewswire/ -- Biotech companies define "well-positioned" with exciting product pipelines and the favorable terms they will be able to negotiate. Find out how to capitalize on their stocks from Andrew Heyward who produced 51% returns in 2001 recommending the best ones: Healthsouth Corp. (NYSE: HRC), Merck and Co. (NYSE: MRK), Immunex (Nasdaq: IMNX), Icos Corp. (Nasdaq: ICOS), ID Biomedical Corp. (Nasdaq: IDBE), and Seattle Genetics Inc. (Nasdaq: SGEN). For the complete report and substantially more extensive commentary on the sector, visit http://www.allstarpicks.zacks.com

Here are the details on Analyst Andrew Heyward`s Stock Picks for today:


The biomedical solutions he has to stem or prevent bleeding in your portfolio include:

Healthsouth Corp. (NYSE: HRC) has been down in the last couple of days because it announced that the Department of Justice would intervene in a whistle blower lawsuit. Heyward says the suit looks limited, though he can`t guarantee the ultimate size of the potential liabilities. He expects the company to earn $1.15/share this year and the stock is selling at only $12.

Merck and Co. (NYSE: MRK) is undervalued based on earnings, says Heyward. The company is selling at a discount to both drugs and the S&P. Historically, the pharma companies sell at a 20-25% premium to the S&P. Once it gets beyond patent expiration issues and back on the moderate growth track its multiples should return to those premium levels, probably some time in `03. Right now earnings are expected to be flat because of patent expirations. A number of drugs that are powering their growth right now and some new ones coming out though most are skeptical of the growth potential of their pipeline. Don`t feel necessarily need to be.

In the biotech-specific area, he has Immunex (Nasdaq: IMNX) rated a hold, but feels it is a very good company with a great product. He feels the company is currently fairly valued based on earnings, but the analyst is thinking about picking up Amgen. Enbrel, Immunex`s drug, will remain the premier TNF- antagonist. The only competing drug is from Johnson & Johnson called Remocade. However, Heyward thinks Enbrel is the best drug in terms of safety and effectiveness. He expects approval for use against psoriasis, and perhaps several other illnesses.

Icos Corp. (Nasdaq: ICOS) has a Buy rating from the analyst who thinks the value of its drug in final stages of approval, Cialis, will be a stiff competitor with Viagra. Icos is co-producing the drug with Eli Lilly. He feels that Cialis could be worth somewhere in the low $40 range/share, and so he thinks investors will get the rest of the company for free as well as a full pipeline. He has a $70 price target based on Cialis approval.

Heyward also wants to mention a couple of companies that he has and eye on for release of human data. ID Biomedical Corp. (Nasdaq: IDBE) has a couple of vaccines that really could be exciting. Seattle Genetics Inc. (Nasdaq: SGEN) also has some interesting antibody technologies it will present data on soon.

Be sure to read the rest of the article for significant industry commentary and more in-depth discussion of stocks poised to perform! http://www.allstarpicks2.Zacks.com About Zacks All Star Analyst Survey

Do you want to know which brokerage analysts are the best stock pickers in their field and what stock they`re recommending today? Find out with the Zacks All Star Analyst survey.

This exclusive survey, created with Fortune Magazine, reveals the "Best- of-Breed" brokerage analysts. They are the select group of winners from a field of 5,500 brokerage analysts - the ones who consistently beat the street - the few you should be following. Visit http://www.allstarhome.zacks.com

Stock Picks from All Star Analysts Highlighted in FREE Investment Newsletter

Each week, Zacks Investment Research highlights another All Star Analyst and their hottest stock picks in the FREE e-mail newsletter, "Profit from the Pros." You`ll also discover the "All Star Portfolio," the exclusive stock list comprised only of stocks where 4 or more All Star Analysts consider it a strong buy. The only way to get these powerful insights is with a FREE subscription to the "Profit from the Pros" investment newsletter. Just visit http://www.freeprofit3.zacks.com About Zacks

Zacks.com is a property of Zacks Investment Research (CRD #7874), which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, then with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofit4.zacks.com

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Visit: www.Zacks.com

CONTACT: Terry Batey of Zacks.com, [phone], ext. 307, [e-mail]

[Schnippelbohne]

Tja,ich glaube ich sollte auch Star-Analyst werden.
Am 28. Januar Icos zum Kauf empfehlen und ein Wimpernschlag später kommt eine Gewinnwarnung. Tolle Analyse, tolles Timing, hätte ich auch noch gekonnt.

Wahrscheinlich hat er aber nur gepusht um seine Icos-aktien noch teuer zu verticken, dann Respekt, so dreist ist sonst nur die Deutsche Bank bei ihren Empfehlungen.

Schnippelbohne

[Wunram]

jetzt hauen sie uns aber auf den Sa..

erst die Meldung die FDA braucht zusätzliche Informationen für die Zulassung von CIALIS

Lilly ICOS LLC Receives Approvable Letter From FDA for Cialis for the Treatment of Erectile Dysfunction

BOTHELL, Wash.--(BUSINESS WIRE)--April 30, 2002--
-- Cialis Moves Closer to Approval With Lilly ICOS LLC to

Provide Additional Data to FDA --

Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Cialis(TM) (tadalafil). Lilly ICOS is seeking approval of Cialis, its investigational oral PDE5 inhibitor, for the treatment of erectile dysfunction. FDA approval is contingent upon successful completion of additional clinical pharmacology studies, labeling discussions and manufacturing inspections.

Regarding the U.S. timeline for Cialis, Lilly ICOS will conduct discussions with the FDA on the exact data requirements requested by the agency for final product approval. The results of these discussions will allow Lilly ICOS to provide a better estimate of the potential U.S. launch date. Currently, a U.S. launch for Cialis is now projected to be in 2003.

"Based on its clinical profile, we are confident in the value and potential of Cialis," said Paul Clark, ICOS chairman and chief executive officer. "This action by the FDA brings Cialis one step closer to approval in the U.S., and we are confident Lilly ICOS can fulfill the FDA`s additional requests in a timely manner."

"We are committed to making Cialis an available treatment option for the more than 30 million American men who are affected by erectile dysfunction," said Sidney Taurel, chairman and chief executive officer of Eli Lilly and Company. "Lilly ICOS will continue working with the FDA to bring this innovative compound to market as expeditiously as possible."

Erectile dysfunction is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. It affects an estimated 152 million men and their partners worldwide and more than 30 million men in the United States, with many cases caused by physical conditions, including cardiovascular disease and diabetes.
.....

und dann eine Gewinnreduktion von Eli Lilly weil CIALIS wohl erst 2003 auf den MArkt kommen wird

Eli Lilly lowers outlook, cites impotence drug delay

INDIANAPOLIS, April 30 (Reuters) - Drugmaker Eli Lilly and Co. (NYSE:LLY) on Tuesday lowered its earnings guidance for 2002, citing a later-than-expected launch of a new anti-impotence drug being co-developed with ICOS Corp. (NASDAQ:ICOS).

Lilly and ICOS said on Tuesday they received conditional approval from U.S. regulators for the new pill, called Cialis, but they do not expect to launch the drug until 2003.

Lilly said it is unsure when the drug will get final approval, but for the purposes of financial planning, the company is not including sales estimates for Cialis this year.

Indianapolis-based Lilly said it expects to earn $2.60 to $2.65 per share for the year, below a previous estimate of $2.70 and $2.80. The company said it expects sales growth to be flat, down from a previous forecast of sales increasing by a percentage in the low- to mid-single digits.

Copyright 2002, Reuters News Service

Folge: vorbörslich ICOS bei rund $32 oder fast -18% gegenüber Schlusskurs gestern

Gruss Wunram

[illai]

Es geht um viel Geld: Der Markt für Medikamente zur Behandlung von Erektions-Störungen ist Milliarden schwer und hält den begehrten Blockbuster-Status für einen entsprechenden Kandidaten bereit. Der Pharma-Konzern Pfizer ist seit 1998 mit Viagra der Platzhirsch auf diesem Gebiet.

Diesem wollen das Biotech-Unternehmen Icos und der Pharma-Konzern Eli Lilly Konkurrenz machen: Cialis heißt der Hoffnungsträger, der in der abschließenden Studie möglicherweise einen wichtigen Vorzug gegenüber dem etablierten Medikament vorzuweisen hat.

[Anzeige]


Mit einer Privaten Krankenversicherung können Sie Monat für Monat bis 200 Euro sparen.

Wir ermitteln aus über 35 Gesellschaften und über 1000 Tarifkombinationsmöglichkeiten den für Sie günstigsten Versicherer. Fordern Sie jetzt ihren persönlichen Preis- Leistungsvergleich an.




Am heutigen Montag wird die Veröffentlichung der Studie erwartet. Vorab ist bekannt geworden, dass Cialis Erektionsstörungen zwischen 24 bis zu 36 Stunden entgegen wirkt. Zwar hat die Studie keinen direkten Vergleich zwischen dem Herausforderer und Viagra gebracht, doch hätten ältere Studien eine maximale Wirkung von Viagra zwischen acht und zwölf Stunden ergeben, meint Dr. Raymond Rosen, Autor der Cialis-Studie, gegenüber US-Medien.

Eine deutlich längere Wirksamkeit wäre ein entscheidender Erfolgsfaktor für Cialis, sagt Dr. Gerald Brock von der University of West Ontario. Benutzer von Viagra müssen die Einnahme des Wirkstoffes gut timen, was sich negativ auf das Sexleben auswirke, so der Professor. Mit dem deutlich länger andauernden Cialis wäre das Problem signifikant abgemildert.

Trotzdem muss Pfizer kurzfristig nicht bange sein. Die Zulassung von Cialis hat sich deutlich verzögert. Ursprünglich hatten Icos und Eli Lilly einen Markteintritt in diesem Jahr vorgesehen, die US-Behörden haben dem aber einen Strich durch die Rechnung gemacht, mit einer Zulassung wird erst 2003 gerechnet. Das Pharma-Unternehmen Bayer steht mit dem Medikamenten-Kandidaten vardenafil ebenfalls in den Startlöchern, um den lukrativen Markt zu erobern.

Autor: Alexander Apel (© wallstreet:online AG),09:58 27.05.2002

[[KERN]Codex]

WL!

[Wunram]

news

Cialis Receives Positive Opinion from European Committee for Proprietary Medicinal Products

INDIANAPOLIS, Jul 25, 2002 (BW HealthWire) -- Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS) announced today that the European Committee for Proprietary Medicinal Products (CPMP) has issued a positive opinion for Cialis(TM) (tadalafil), an investigational oral PDE5 inhibitor for the treatment of erectile dysfunction. The CPMP has recommended to the European Commission that approval should be granted.
"We are extremely pleased by the CPMP`s recommendation for approval of Cialis in Europe," said Richard Pilnik, president of European operations for Lilly. "This positive action by the CPMP brings Cialis one step closer to approval and launch in the European Union, and will soon help bring a new therapy to millions of men who suffer from ED."

"Based on its clinical profile, we are confident in the value and potential for Cialis," said Paul Clark, ICOS chairman and chief executive officer. "ED is a significant problem. In Europe alone, an estimated 31 million men suffer from the condition."

The CPMP, comprised of regulators from the European Union countries, based its positive opinion on its review of the comprehensive data package of Cialis. The submission was comprised of more than 60 studies in more than 4,000 humans to characterize the safety and efficacy profile of Cialis.

Following the CPMP`s positive opinion, the application will be reviewed by the European Commission, which has authority to grant marketing authorization for the European Union. This authorization is anticipated for later this year.

About Erectile Dysfunction

Erectile Dysfunction is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. ED affects an estimated 152 million men and their partners worldwide.(1) Up to 80 percent of ED cases are caused by physiological conditions, including cardiovascular disease and diabetes, with psychological factors accounting for the remaining 20 percent. In many cases, however, both psychological and physical factors contribute to the condition.(2)

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is developing tadalafil for the treatment of sexual dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations. Headquartered in Indianapolis, Indiana, Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases, and inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing the Company`s opportunities to market breakthrough products.

Certain of the matters discussed herein with respect to clinical studies and ICOS and Lilly`s products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product.



(1) Aytac et. Al BJU International, 1999:84:50-56.

(2) Impotence World Association, www.impotenceworld.org

CONTACT: Lilly Jill Schaefer, 317/277-3661 Frances Beves, 44 127 648 4810 or ICOS Lacy Fitzpatrick, 425/415-2207

[skaya]

@all
hi, nächste Zahlen lt. Yahoo.Finance am 24.10.2002
nach Börsenschluss. Prognose: -0,57
Grüße
Skaya

[skaya]

hi,
die Zahlen kommen nicht am 24.10,
sondern jetzt am 05.11. nach Börsenschluss.
Grüße
Skaya

[Wunram]

yeesss!

REPEAT/Cialis -- tadalafil -- Approved by European Commission for the Treatment of Erectile Dysfunction

BOTHELL, Wash. & INDIANAPOLIS--(BUSINESS WIRE)--Nov. 14, 2002-- Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS) announced today that the European Commission has granted a marketing authorization for Cialis(TM) (tadalafil), an oral PDE5 inhibitor for the treatment of erectile dysfunction (ED) for all 15-member states of the European Union. The approval decision follows a positive opinion adopted July 25, 2002, by the European Committee for Proprietary Medicinal Products (CPMP).

Lilly ICOS anticipates launching Cialis in Europe during the first half of 2003.

The European Commission based its decision on the review and evaluation of the comprehensive data package of Cialis that comprised results of more than 60 studies in more than 4,000 people to characterize the safety and efficacy profile of Cialis. The randomised, placebo-controlled, Phase 3 primary efficacy studies of Cialis involved 1,112 men (804 Cialis, 308 placebo) with ED of various causes and severity and evaluated doses including 10 and 20 mg.

"Not only is the approval of Cialis a significant milestone for Lilly ICOS, but we believe it is an important step forward for millions of men in Europe who suffer from ED," said Paul Clark, ICOS chairman and chief executive officer.

"Cialis will provide an important new treatment option for many of the 31 million men in Europe with ED," said Richard Pilnik, president of European operations for Lilly.

About ED


ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. ED affects an estimated 152 million men and their partners worldwide(1). Up to 80 percent of ED cases are caused by physiological conditions, including cardiovascular disease and diabetes, with psychological factors accounting for the remaining 20 percent. In many cases, however, both psychological and physical factors contribute to the condition(2).

About Lilly ICOS LLC


Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is developing tadalafil for the treatment of sexual dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. The Company combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. The Company applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases, and inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing the Company`s opportunities to market breakthrough products.

Certain of the matters discussed herein with respect to clinical studies and ICOS and Lilly`s products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product.

1. Aytac IA, McKinlay JB, Krane RJ. The Likely Worldwide Increase
in Erectile Dysfunction Between 1995 and 2025 and Some
Possible Policy Consequences. BJU Int 1999; 84: 50-56.

2. Impotency Information from NIH. NIH Publication No. 95-3923.
1995


CONTACT: Eli Lilly
Carole Copeland, 317/277-3661
or
ICOS
Lacy Fitzpatrick, 425/415-2207

Copyright 2002, Business Wire.

[MichiZocker]

Hi wunram, guter bericht aber könntest du ihn mir nur ein bissle übersetzen Danke wäre echt hilfreich Danke

[Wunram]

los gehts wie von ICOS versprochen

Press Releases

ICOS Announces First Shipment of Cialis in Europe

BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 22, 2003--ICOS Corporation (Nasdaq:ICOS) ("ICOS") announced today that Cialis(TM) (tadalafil), an oral PDE5 inhibitor approved in Europe for the treatment of erectile dysfunction (ED), is now being shipped to European distributors. Cialis(TM) is expected to be available, by prescription, in pharmacies across the European Union within the next few weeks.

"The first commercial shipment of Cialis(TM) is a groundbreaking event for ICOS, which has been developing Cialis(TM) for over eight years," stated Paul Clark, ICOS` chairman, president, and chief executive officer. "Cialis(TM) is an important advance in the treatment of ED for patients in Europe."

Lilly ICOS LLC ("Lilly ICOS"), a joint venture between ICOS Corporation and Eli Lilly and Company, is developing Cialis(TM) for the treatment of ED and other indications. Cialis(TM) was granted marketing authorization by the European Commission on November 12, 2002. In the U.S., Lilly ICOS received an approvable letter for Cialis(TM) from the U.S. Food and Drug Administration ("FDA"). Lilly ICOS presently expects an FDA regulatory decision regarding Cialis(TM) in the second half of 2003.

ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products with significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, psoriasis, sepsis, and inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS` results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in ICOS` latest Annual Report on Form 10-K and its other SEC filings.


CONTACT: ICOS Corporation Lacy Fitzpatrick, 425/415-2207


Terms of use © 2001, 2002, 2003 ICOS

[Wunram]

die Briten dürfen anfangen

Lilly to launch Viagra rival in UK next week
27 Jan 2003, 09:12am ET

- - - - -

LONDON, Jan 27 (Reuters) - Eli Lilly and Co (NYSE:LLY) said on Monday it would launch its anti-impotence drug Cialis in Britain next week, signalling the start of a multi-billion-dollar battle for a market so far dominated by Pfizer Inc`s (NYSE:PFE) Viagra.

Cialis, developed with U.S. biotechnology company Icos Corp
(NASDAQ:ICOS), is being rolled out for the treatment of impotence in Europe, ahead of the United States.

Britons will be first in Europe to receive the drug, which
Lilly claims acts faster and lasts longer than Viagra.

Cialis was approved by European regulators in November but
Lilly was not able to launch it immediately because of a switch in manufacturing sites.

In the United States, Cialis has an "approvable letter" from the Food and Drug Administration, indicating the authorities are ready to approve the product pending resolution of some outstanding issues. Its U.S. launch is expected in the second half of 2003.

GlaxoSmithKline Plc (ISEL:GSK) and Bayer AG expect to
launch their new impotence drug Levitra this year, and industry analysts expect a fierce fight between rival products.

Viagra has been a huge commercial success for Pfizer, raking in 2002 sales of $1.74 billion and establishing itself as the world`s most famous pharmaceutical brand.

Viagra, Levitra and Cialis all work by blocking an enzyme
known as PDE-5 which affects blood flow in the body. Industry analysts estimate the total market for such drugs could hit $4 billion by 2006.

Copyright 2003, Reuters News Service

[lucakevin]

Guten Morgen Wunram,
der Chart sieht sehr gut aus und mit den Meldungen der letzten Tage werden wir uns bald über steigende Kurse freuen dürfen.Gruss

[Guuruu]

durchbrochener bearkeil mit bereits erfolgtem pullback im Wochenchart.

Sieht eher katastrophal aus,

aus meiner Sicht,

grüsse

[Wunram]

heute gibts Quartalszahlen

erwartet wird ein Ergebnis, sprich Verlust von -75 Cent je Aktie. Letztes Q4 waren es 62 Cent miese.

Gruss Wunram

[lucakevin]

Am 3.Feb. kommt Cialis auf den europäischen Markt.Wie seht Ihr die realistische Kursentwicklung für dieses Jahr.
Gruss

[Wunram]

[Zahlen]

Q4 2002 -76 Cent /Aktie

2002 -2,64 $ /Aktie

Gut N8

[Wunram]

auführlich

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=ICOS&…

[Wunram]

mal sehen was das für ICOS bedeutet.

Texas Biotechnology to Reacquire Full Development and Marketing Rights To Sitaxsentan

30 Jan 2003, 5:00pm ET

Company to Present Phase IIb/III Clinical Results at American Thoracic Society Meeting

Conference Call Scheduled for Friday, January 31, 2003 at 8:30 AM Eastern Time Dial-In Number: 612-288-0329

HOUSTON, Jan. 30 /PRNewswire-FirstCall/ --
Texas Biotechnology Corporation (NASDAQ:TXBI) today announced that the Company plans to reacquire full development and worldwide marketing rights to the pulmonary arterial hypertension drug, sitaxsentan, from ICOS-Texas Biotechnology, L.P., a partnership formed by Texas Biotechnology and ICOS Corporation (NASDAQ:ICOS) in June 2000. Sitaxsentan will be evaluated in a second pivotal phase III study beginning in the second quarter.
"We are pleased to have the opportunity to reacquire this core asset," Bruce D. Given, M.D., President and CEO of Texas Biotechnology said.
"Sitaxsentan is Texas Biotechnology`s lead product, and we are excited by its potential as a new option in the treatment of pulmonary arterial hypertension.
Building upon ICOS` considerable contributions to the development of this drug, we are well positioned to bring this product through registration."
Under the ICOS-Texas Biotechnology L.P. agreement, research, development and marketing costs were to be shared equally, as were profits on any product sales. An initial focus of the joint venture was to initiate a Phase IIb/III pulmonary arterial hypertension trial for sitaxsentan, which has been completed and top-line results were announced in October 2002. The financial terms of this transaction are subject to ongoing negotiations between the two companies.
Texas Biotechnology recently reached an agreement with the U.S. Food and Drug Administration regarding the requirements for the second pivotal sitaxsentan trial, and the Company intends to launch the STRIDE II Trial
(Sitaxsentan To Relieve ImpareD Exercise in pulmonary arterial hypertension)in the second quarter of 2003.

Sitaxsentan Results to be Presented at the American Thoracic Society Annual Meeting
The American Thoracic Society has accepted two abstracts -- one oral presentation and one poster presentation -- on the results of the STRIDE Phase IIb/III trial. Texas Biotechnology will present these abstracts at the
Society`s annual meeting in Seattle, Wash., May 16 - 21, 2003.
"Sitaxsentan will be the second product Texas Biotechnology has the opportunity to bring through FDA approval, after our successful registration of Argatroban," continued Dr. Given. "The Company ended 2002 with approximately $67 million in cash, and possesses the proven expertise to manage this final stage of clinical development. Reacquiring sitaxsentan is expected to change cash utilization for the company. We expect to provide preliminary, updated financial guidance in February for 2003."

About Sitaxsentan and PAH
Sitaxsentan is a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. Endothelin receptor antagonists may prove to be effective in the treatment of a variety of diseases where the regulation of vascular constriction is important. Sitaxsentan is selective in the targeting of the endothelin A receptor.
Pulmonary arterial hypertension is a condition that involves high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs.
PAH causes shortness of breath, limits activity, and is eventually fatal unless treated successfully with heart and lung transplant. Primary and secondary pulmonary arterial hypertension are estimated to afflict up to
100,000 people worldwide, many of whom are children or young adults.
Texas Biotechnology will host a conference call on Friday,
January 31, 2003 at 8:30 AM Eastern. To participate in the call, dial 612/288-0329 and ask for the Texas Biotechnology conference call. A replay of the conference call will also be available beginning at 10:15 AM Eastern on Friday, January 31 and will end on Saturday, February 1 at 11:59 PM Eastern.
To access the replay dial 800/475-6701 in the United States and [phone] for International access. The access code for the replay is 673941. In addition, the conference call will be available live on the Company`s web site www.tbc.com. A replay of the conference call will also be available on the Company`s web site.

About Texas Biotechnology
Texas Biotechnology, a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for its expertise in small molecule drug development and vascular biology.
Argatroban, its first FDA-approved product, is being marketed by GlaxoSmithKline for heparin-induced thrombocytopenia. Texas Biotechnology is in Phase III development of the endothelin antagonist, sitaxsentan, for
pulmonary arterial hypertension. Texas Biotechnology has several other research and development programs ongoing for a range of cardiovascular and inflammatory diseases. To learn more about Texas Biotechnology please go to
our web site: www.tbc.com .
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are timing and cost of our clinical trials, attainment of research and clinical goals and milestones of product candidates, attainment of required governmental approvals, sales levels of our products and availability of financing and revenues sufficient to fund development of product candidates and operations. In particular, careful consideration should be given to cautionary statements made in the various reports Texas Biotechnology has filed with the Securities and Exchange Commission. The Company undertakes no duty to update or revise these forward-looking statements.

Texas Biotechnology Corporation
01/30/2003

[lucakevin]

Hallo Wunram,
warum geht ICOS im Moment so stark nach unten?
Nach den letzten Meldungen sollte es eigentlich so langsam nach Norden gehen.
Gruss

[Wunram]

@lucakevin

ich hab´keine Ahnung.

Momentan hab ich wenig Zeit für Aktien - zu viel richtige Arbeit.

Ich finde keine Meldung. Vielleicht die Reaktion auf die Verfügbarkeit des Konkurrenzproduktes von Bayer/GlaxoSmithKline Levitra ab Mitte März?? Obwohl die Meldung ja schon am 4.2.2003 kam!

vom Intradaytief sind wir aber schon wieder ganz schön hochgekommen.


Sonst noch jemand eine Ahnung??
Wunram

[Wunram]

die Meldung kanns ja wohl nicht sein:

Cialis -tadalafil- to Sponsor America`s Cup 2003

AUCKLAND, New Zealand, Feb 10, 2003 (BUSINESS WIRE) -- Earlier today in Auckland, New Zealand, Lilly ICOS announced that it will be a major sponsor of the America`s Cup 2003 scheduled to begin on 15 February. The sponsorship is on behalf of Cialis(R), the new oral treatment for erectile dysfunction (ED).

Developed and marketed by Lilly ICOS, Cialis was recently launched in Australia and some member states of the European Union. It will be available in New Zealand on 24 February.

The best-of-nine race America`s Cup 2003 features the defenders, Team New Zealand, taking on the challenge of the Swiss team, Alinghi.

For more information contact Ashley Abbott, America`s Cup, [phone] or Angela Sekston, Lilly, at [phone].

Lilly
Angela Sekston, [phone]
or
America`s Cup
Ashley Abbott, [phone]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.


Gut´N8

[Wunram]

mal so, mal so

Bear Stearns & Co., Inc. (SWFT, IPG, LTD, ICOS, CVC, MET, WLP, FNM, SCIO, CKP, SNN, JNJ, TVL)

11 Feb 2003, 07:24am ET
- - - - -
.....

ICOS: Reit Outperform - We believe that the recent weakness in ICOS shares based on comments questioning the safety and efficacy profile of Cialis are overblown. We would like to point out that the original documents relating to the Cialis label in the EU have been available on the EMEA website since November 2002. Furthermore, no new data on Cialis has been presented since the ESSIR meeting in December 2002. We reiterate our Outperform rating on ICOS. We expect competition to be fierce as Pfizer prepares to defend its monopoly on PDE5 inhibitors for the treatment of erectile dysfunction which it has held since 1998. Viagra sales last year were slightly over $1.7 billion.
.....
Click below to read more about subscribing to the full JAGnotes product.

http://www.jagnotes.com/c/23/98.cfm?pagetitle=SubscribeNow Copyright 2003 JAGfn.com All Rights Reserved

**-----------------------------------------------------------**

Capital Research Group Announces Investment Opinion: Stock Watch List!

11 Feb 2003, 07:44am ET

- - - - -
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc., a Member of the National Association of Securities Dealers, CRD Number 2955420.

Watch Genesis Technology Group Inc. (OTC BB: GTEC). GTEC is expanding with a new office in California that management believes will be instrumental in closing millions of dollars in new business from the Pacific Rim with exposure to 40 new companies in the next few months. Watch for the stock to move as the Company executes its growth strategy! Other stock market standouts include: FiberNet Telecom Group (NASDAQ: FTGX): Market Perform, up 16% on 38 million shares, EMC Corporation (NYSE: EMC): Market Perform, up 7% on 19 million shares, ICOS Corporation (NASDAQ: ICOS): Market Underperform, down 7% on 5 million shares.

......

Contact: Charles T. Tamburello
Company: Capital Research Group Inc., Weston
Voice: 954-217-9555
Fax: [phone]
Email: [e-mail]

[1.000000]

icos !! jetzt kaufen

[Guuruu]

ohne jemanden zu nahe tretenzuwollen denke ich,

das Hoch vom 28.03 wäre der ideale Vekaufspunkt gewesen.

grüsse

[lucakevin]

Wenn ICOS von der FDA die Zulassung für USA bekommt ist es schnurz wie der Chart aussieht

[Guuruu]

Der Chart hat recht,

und ich auch,

sorry

[Guuruu]

pullback bis zu Flagge ?

[KMS]

Cialis wird einen hohen Umsatz generieren.
Es wird ein Blockbuster, und Viagra übertreffen.
Die Kurse von Icos sind ein Witz.


KMS

[KMS]

Cialis ist erst ein paar Wochen auf dem deutschen Markt.
Die Verkauszahlen steigen rasant.
Es ist einfacher als Viagra anzuwenden.
Der Kurs springt in Amiland gerade an, denn die haben das auch bemerkt.
Ich habe mir heute mal ein paar Stücke geholt.

KMS

[KMS]

Aktueller Auszug aus stern.de:

Attacke auf das blaue Monopol

© Erich Lessing/AKG

.....Anders als Viagra verfügt Cialis (vier Tabletten ? 10 mg kosten 47,99 Euro; die Vierer-Packung Viagra in der entsprechenden 50-mg-Dosierung ist einen Cent teurer) nicht nur über ein "Wirkfenster" von vier bis acht Stunden, sondern von 24 bis 36 Stunden. Außerdem stört ein romantisches Abendessen zu zweit die Pillenwirkung nicht.

"Die längere Wirkungsdauer von Cialis ist ein ganz entscheidender Vorteil", sagt der Münchner Sexualmediziner Ulrich Pickl. Bei sensiblen Männern könne nämlich schon der Gedanke, innerhalb einer bestimmten Zeitspanne "funktionieren zu müssen", eine Erektion verhindern.

Viagra-Hersteller Pfizer, seit der Markteinführung seines "blauen Diamanten" 1998 quasi Alleinherrscher auf dem ED-Markt, macht gute Miene zum bösen Spiel. Geoffrey Cook, der New Yorker Sprecher des mächtigsten Pillenmultis der Welt, erklärte gelassen, man erwarte nicht, dass Cialis den Erfolg von Viagra schmälern könne. Das gelte auch für den zweiten neuen Rivalen, das Versteifungsmittel Levitra. Die pfirsichfarbene Rundpille mit dem Bayer-Kreuz wird bei uns wahrscheinlich ab Jahresmitte erhältlich sein.

[KMS]

ICOS nachbörslich stark.

KMS

[KMS]

Icos zieht in den USA schön an.
Sonst keiner dabei?

KMS

[KMS]

ICOS +5%!
Die Amis decken sich auch heute wieder ein, nachden zu Handelsbeginn Gewinnmitnahmen erfolgten.

KMS

[lucakevin]

Hallo Guuruu,
wie sieht der Chart nun aus?Wann ist der richtige Zeitpunkt um zu verkaufen?
Warum steigt ICOS nur?

[KMS]

Nasdaq100-Gewinner heute: ICOS.

Good-Luck
KMS

[lucakevin]

ICOS nachbörslich bei 25.20 USD!!!!!!!!

[Guuruu]

@lucakevin

knappe 15 % ist sie gefallen nach meinem posting..

aber Du hast recht,
mittelfristig wäre Verkaufen ein Fehler gewesen,
aus heutiger Sicht,

gratuliere

[lucakevin]

hallo Guuruu, finde es klasse wie du reagierst.
hast du nicht ein paar gute aktien auf lager die charttechnisch im moment gut aussehen und von denen du überzeugt bist.
gruss lucakevin

[KMS]

Aktuell:
ICOS 28,50 $ (+6 %).
ICOS ist wirklich der heimliche Star!

Ich bleibe investiert.
Da ist m. E. noch viel Luft nach oben.
Einer der Hauptumstzträger bei PFIZER ist Viagra.
Und genau hier jagt ICOS PFIZER Umsatzanteile ab, und zwar zunehmend.

Ich will kein Kursziel angeben.
Wer will eine erste Prognose auf Sicht von 1-2 Jahren abgeben?

KMS

[KMS]

Testsieger Cialis

Erster Pluspunkt: Insgesamt 60 Studien die an rund 4000 Probanden durchgeführt wurden, bescheinigen der neuen Wunderpille Cialis erheblich weniger Nebenwirkungen als dem Pfizer-Präparat Viagra - dessen erfolgreiche Markteinführung vor 4 Jahren ist, so ist sich die Fachwelt einig, vor allem auf den First-Mover-Effekt zurückzuführen. Doch was kann der Nachzügler Cialis noch besser? Pluspunkt Nr.2: Das Präparat des US-Pharmakonzerns Eli Lilly und Icos Corp. beginnt binnen 15 Minuten zu wirken. Laut dem britischen Wissenschaftsmagazin Science hält die Erektion nach der Einnahme von Cialis zwischen 24 und 36 Stunden an. Somit hat das neue Helferlein in Sachen Standfestigkeit eindeutig die Nase vorn. Das Pfizer-Produkt Viagra braucht für harte Tatsachen immerhin eine Stunde - und der Wirkungszeitraum liegt mit höchstens 12 Stunden weit hinter der neuen US-Superpille...

KMS

[kurttilly]

Was ist mit unserem Testsieger "Cialis" los????? Warum verliert ICOS über 8% ???

[KMS]

kurttilly

Ich vermute, das sind die längst fälligen Gewinnmitnahmen.
Es sieht aber so aus, als ob die 25-Euro-Marke verteidigt wird.
Ich überlege, hier nachzukaufen.


MfG

KMS

[KMS]

Ich meinte natürlich die 25-$-Marke.

KMS

[kurttilly]

Hallo KMS!

Diese Artikel fand ich heute über www.finanznachrichten.de:

Icos und der Kampf der Potenzmittel
[ 02.05.03, 11:00 ]
Von Günter Pollersbeck




Mit einem Verlust von 40 Millionen Dollar oder 65 Cent je Aktie schloss Icos die ersten drei Monaten des Jahres 2003 ab. Das liegt fast genau auf Vorjahresniveau.






Bald Cialis-Swinger? Der bekennende Polygam und Viagra-Patient Hugh Hefner.


Analysten hatten aber mit 82 Cent je Anteilschein gerechnet. Die geringeren Umsätze, die Folge von zwei beendeten Forschungskooperationen sind, glich die Gesellschaft durch deutlich reduzierte operative Kosten aus.

Die entscheidende Frage aber lautet: Wie gut verkauft sich das Potenzmittel Cialis auf dem europäischen Markt? Denn seit Februar 2003 vermarktet Icos gemeinsam mit dem Pharmakonzern Eli Lilly den Muntermacher in der EU.


BUSINESS NEWS May 2, 2003



Lilly, ICOS say still answering FDA Cialis queries
2003-05-02 12:39:34 EST

NEW YORK, May 2 (Reuters) - Eli Lilly and Co. and ICOS Corp. said on Friday they expect to soon send a letter to U.S. regulators to answer questions about their experimental erectile dysfunction drug Cialis.

The companies, which operate a joint venture called Lilly ICOS, said they expect the treatment to be approved in the second half of this year, as expected.

However, the announcement on Friday showed that the companies are still responding to U.S. Food and Drug Administration queries about the medicine. The drug was granted conditional approval in April 2002.

Shares of ICOS, which is highly dependent on the future of Cialis, fell 8.5 percent to $25.70 in early afternoon Nasdaq trading, while Lilly`s stock was up 29 cents to $64.41.

The drug is among a handful of new rivals to Pfizer`s Inc. famous anti-impotence drug Viagra. The U.S. Food and Drug Administration is reviewing applications for Cialis, Levitra, made by Bayer AG and GlaxoSmithKline , and Uprima, developed by TAP Pharmaceutical Products Inc.


BUSINESS NEWS May 2, 2003



UPDATE 1-ICOS, Lilly say yet to provide Cialis data to FDA
2003-05-02 14:45:30 EST

(Recasts, adds background, analyst comments, byline)

By Bill Berkrot

NEW YORK, May 2 (Reuters) - Eli Lilly and Co. and ICOS Corp. said on Friday they have not yet provided data on their impotence treatment Cialis requested by U.S. regulators but still expect to launch the Viagra rival in the second half of 2003.

Shares of ICOS, the smaller partner in the joint venture that will market Cialis, fell almost 11 percent after the announcement confirmed Wall Street suspicions that the requested data had not yet been submitted to the U.S. Food and Drug Administration, analysts said.

Analysts also said ICOS shares fell on investor concern that another new impotence treatment made by GlaxoSmithKline and Bayer AG , called Levitra, would have a greater chance now of beating Cialis to market.

"This clarification today puts to bed the speculation that ICOS had already submitted their data. For those who had been thinking the approval of Cialis would come earlier in the second half of 2003 than later, that may not be quite as certain," said Chris Raymond, an analyst with Robert Baird & Co.

"I think there`s a misperception that if Levitra is on the market in August that there would be a significant disadvantage to Cialis," Raymond also said.

The FDA gave Cialis conditional approval in April 2002, meaning the drug had to clear a number of hurdles before it could get the final green light to go to market.

Lilly and ICOS said the FDA had requested specific information about Cialis but they declined to say what it was, creating some nervousness among investors that the agency might have safety concerns.

An FDA advisory panel is scheduled to review Levitra on May 29, which could set the stage for its approval shortly afterward.

Lilly confirmed on Friday that Cialis will not be reviewed at that meeting and again declined comment on what type of information the FDA is seeking.

Bothell, Washington-based ICOS, whose future hinges on Cialis, was down $2.96, or 10.5 percent, at $25.14, in heavy afternoon trading on the Nasdaq. Lilly, which makes a wide variety of medicines, edged down 9 cents to $64.03 on the New York Stock Exchange.

Both Cialis and Levitra are already sold in Europe and other markets, but the bulk of future sales are expected to come from the United States if they are approved.

Pfizer Inc`s famous anti-impotence drug Viagra boasts annual sales of about $2 billion. (Additional reporting by Ransdell Pierson and Jed Seltzer)


Kann mir bitte jemand kurz erläutern, worum`s hier geht???

Danke im Voraus!

Kurttilly

[KMS]

kurttilly,

Der Konkurrent Levitra von Bayer hat mit 5 Stunden bei weitem nicht die Wirkdauer von Cialis.
Und damit ist Cialis das zukünftig aussichtsreichste Mittel!

Außerdem: Der Markt ist riesig, da haben auch mehrere Konkurrenten Platz.

ICOS wird sich wieder erholen.

KMS

[KMS]

Schade, ICOS scheint niemanden hier zu interessieren.
Ich bin weiter dabei, heute +12 %!

Bei rund 40 $ würde ich erstmals ein paar Gewinne mitnehmen und den Rest weiter laufen lassen.


KMS

[Bullebio]

Hallo an alle ICOS fans. am dienstag kamen zahlen über die verkäufe in deutschland auf dem markt. icos hat es geschafft, 17 wochen nach verkaufsstart in deutschland einen marktanteil von 28 % zu ergattern. viagra von pfizer besitzt derzeit einen marktanteil von knapp 60 %. die restlichen % teilen sich bayer und etwaige potenzmittel. es ist unglaublich, wie sich cialis von icos gegenüber viagra von pfizer durchsetzen kann, ohne große werbung und bla bla. ich gehe davon aus, das cialis mind. in 1-2 jahren einen marktanteil von 40 % in deutschland besitzen wird. die wirksamkeit, keine nebenwirkungen sind gegenüber viagra die fakten. sowie ich den analystenkommentar verstanden habe, hat icos alleine in deutschland im 2. quartal 30 mio eu umgesetzt. ich hoffe, das die fda im 3. quartal in usa cialis freigibt. wenn man es hochrechnet, gehe ich davon aus, das cialis mind. 1-1,5 mrd USD in 1-2 jahren weltweit umsetzen kann. die derzeitige markt cap beträgt ca. 2 mrd usd. bei einem gerechtfertigten KUV würde dies eine markt cap bei icos von 10 mrd USD rechtfertigen. unberücksichtigt hier ist die weitere produktpipeline von icos. also für mich kursziel mind. 150 USD.
frage: wie werden die umsätze zw. icos und eli lilly aufgeteilt?? 50 zu 50 oder??

[okujawa]

Ich denke wir kommen noch einmal auf 30 $ zurück und dann werde ich noch ein paar eisammeln.
Gestern -6% wahrscheinlich auf Grund der FDA Entscheidung zum Konkurenzprodukt Levitra.
Cialis werden allerdings, mit Abstand die größten Chancen auf dem Weltmarkt eingeräumt.
Sieht doch gut aus, endlich ist "Erntetag"
Gruß
OK

[gigalooser]

zur aufteilung:

Quelle: Homepage von Icos

Eli Lilly and Company
ICOS and Eli Lilly formed a 50/50 owned joint venture to develop and globally commercialize phosphodiesterase type 5 inhibitors (PDE5) as oral therapeutic agents for the treatment of both male and female sexual dysfunction.
(agreement entered: Oct. 1998)

For collaborations and licensing information:
Clifford J. Stocks
Vice President
Business Development
phone [phone]
fax [phone]
[e-mail]


zu den Mitbewerbern ist zu sagen das derzeit ca. 12 Medikamente in der Richtung entwickelt werden oder schon am Markt sind. hab ich vor einiger zeit mal rausgesucht. verkauft wird das mittel sicher über die wirksamkeit. daher sehe ich weniger problem bei der marktdurchdringung. ist ja einfach so das man bei dem mittel eher etwas probiert als bei einem herzmedikament.

g.

[MichiZocker]

Ich kenne eine aktie die sehr attraktiv ist habe mir da heute schon welche gesichert China Pharmaceutical Wkn 548183. steht momentan bei ,031 und hat ein kursziel von 1 euro schau einfach mal nach.

[Wunram]

hält eben einfacher länger

Men Taking Cialis -- tadalafil -- Reported Intercourse Success at 24 and 36 Hours After Taking the Medication Being Developed by Lilly ICOS

5 Jun 2003, 08:29am ET

BOTHELL, Wash. & INDIANAPOLIS--(BUSINESS WIRE)--June 5, 2003--For release in the United States--The majority of men who took Cialis(TM) (tadalafil), an investigational oral treatment for erectile dysfunction (ED) being developed by Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS), reported a successful intercourse attempt at 24 or 36 hours after taking the medication, according to research published in the June 2003 issue of Urology.

"Cialis was statistically superior in the study, compared to placebo, in allowing men with ED to successfully engage in intercourse at 24, and even 36 hours after taking the drug," said study author Professor Dr. Hartmut Porst, leader of a private urological and andrological institute in Hamburg, Germany. "Cialis showed consistent effectiveness at both time points."

In the Cialis group, 61 percent (P less than 0.001) of patients reported a successful intercourse attempt at 24 hours compared to approximately 37 percent for the placebo group. At 36 hours, 64 percent (P less than 0.001) of patients taking Cialis reported a successful intercourse attempt against 35 percent with placebo. A successful intercourse attempt was defined as the ability of a man to achieve and maintain an erection to the completion of sexual intercourse. Of all intercourse attempts at the 36-hour time point, 59 percent were successful for patients on Cialis versus 28 percent for those on placebo (P less than 0.001). For intercourse attempts at 24 hours, 53 percent were successful for patients on Cialis versus 29 percent for those on placebo (P less than 0.001).

As stated in the publication, "The extended period of responsiveness afforded by tadalafil, which has a terminal half-life of 17.5 hours, may begin to change the treatment paradigm for men with ED." Dr. Porst continued, "Unlike currently available treatments, tadalafil may, for example, enable a patient to take a pill on a Friday evening and have intercourse with his partner on Saturday night or Sunday morning and may allow men and their partners more freedom in the timing of their sexual activity."

The most commonly reported (greater than 3 percent) treatment-emergent adverse events with Cialis in the study were headache, flushing, upset stomach and mylagia. There were no color vision abnormalities reported. Two percent of patients (n=3) taking Cialis discontinued the study due to side effects versus 0.5% for placebo. There were no serious adverse events reported after treatment was started.

Cialis Period of Effectiveness -- Study Methodology

The Phase III trial conducted at 36 centers in the United States and Europe was designed to evaluate the primary endpoint of percentage of successful sexual intercourse attempts at specific time points -- 24 and 36 hours -- after dosing. The study included 348 men with mild-to-severe ED and randomly assigned patients to receive Cialis 20 mg (n=175) or placebo (n=173) over an approximate eight-week period with no restrictions on alcohol or food intake. Patients were advised to attempt intercourse with their respective partners on four specific occasions: on two occasions at about 24 hours after dosing, and on two occasions at about 36 hours after dosing. The results are from data recorded between 22 and 26 hours (categorized as the 24-hour time point), and between 34 and 38 hours (categorized as the 36-hour time point).

About Cialis

Lilly ICOS received an approvable letter for Cialis from the Food and Drug Administration in April 2002 and anticipates a U.S. regulatory decision for Cialis later in the second half of 2003. Cialis is available in approximately 30 countries including countries in Europe, Australia, Brazil, Russia and Saudi Arabia.

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. Up to 80 percent of ED cases are caused by physiological conditions, including cardiovascular disease and diabetes, with psychological factors accounting for the remaining 20 percent. In many cases, however, both psychological and physiological factors contribute to the condition.

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is developing Cialis for the treatment of erectile dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, psoriasis, sepsis and inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

Certain of the matters discussed herein with respect to clinical studies and commercial plans for ICOS and Lilly`s products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will receive regulatory approvals as expected or achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. The companies undertake no duty to update forward-looking statements.

CONTACT: Lilly ICOS LLC
Carole Copeland, 317/277-3661 (Lilly)
Lacy Fitzpatrick, 425/415-2207 (ICOS)

SOURCE: Lilly ICOS LLC

[Wunram]

UPDATE 1-Icos, Biogen end drug development pact
6 Jun 2003, 08:19am ET


(Recasts first paragraph, adds details paragraphs 3, 5-6)

NEW YORK, June 6 (Reuters) - Icos Corp. (NASDAQ:ICOS) and Biogen Inc. (NASDAQ:BGEN) on Friday said they terminated a collaboration to develop a group of experimental drugs after one of the treatments failed to work in a clinical trial for psoriasis.

As a result of the termination of the deal, Icos will record a second-quarter gain of about $21 million, or 34 cents per share, for upfront fees and forgiven loans.

One of the drugs, called IC747, was being developed for inflammatory conditions such as the skin disorder psoriasis. But an early-stage clinical trial showed the drug was not effective enough to warrant further development, Icos said.

Icos, which is based in Bothell, Washington, also said on Friday it had agreed with Eli Lilly and Co. (NYSE:LLY) to manufacture two experimental medicines for Lilly, the larger drugmaker. The companies already collaborate on impotence drug Cialis.

Shares of Icos, which jumped 17 percent on Thursday after positive clinical trial data was released about Cialis, were trading at $40 in pre-market electronic trading, above the Thursday`s closing price of $38.90. Cialis is being reviewed by U.S. regulators and is already available in Europe.

Shares of Biogen, maker of multiple sclerosis drug Avonex and psoriasis treatment Amevive, rose to $49.50 in pre-market trading, up from a closing price of $49.14 on Nasadaq.

[Wunram]

na ein paar Kopfschmerzen ist es doch wert

UPDATE 1-New studies show Lilly, Icos impotence drug safe


25 Jun 2003, 1:32pm ET

NEW YORK, June 25 (Reuters) - Drugmakers Eli Lilly and Co. (NYSE:LLY) and Icos Corp. (NASDAQ:ICOS) said on Wednesday clinical trials of their new anti-impotence drug showed it to be safe, with only minor side effects.

The drug, Cialis, which is already sold in Europe but is awaiting approval in the United States and Canada, is expected to compete with Pfizer Inc`s (NYSE:PFE) Viagra.

The new data, presented at the Canadian Urological Association meeting in Toronto, found the most common adverse side affects to be headache and upset stomach.

The U.S. Food and Drug Administration in April 2002 had given conditional approval of the drug, but said final approval was dependent on further data. The two companies have never said what the FDA was seeking, but analysts have speculated that it was a safety issue due to the length of time the drug remains in the system.

The 18-month study of 1,100 men with erectile dysfunction showed the side effects occurred in about 10 percent to 15 percent of patients. Of those, 6 percent stopped taking the drug due to side effects.

The companies said any single side effect, such as headaches, accounted for less than 1 percent of discontinuations.

A second study of safety and tolerability in patients who were also taking medication for high blood pressure showed no increase in adverse side effects, the companies said.

Icos shares were up $1.57, or 4.3 percent at $38.32 in trade on Nasdaq. Eli Lilly shares were off 7 cents to $68.59 on the New York Stock Exchange.

[Wunram]

erst Americas Cup jetzt PGA Tour - ein bisschen exklusiveres Sponsoring durch ICOS

Lilly ICOS Signs Multiyear Agreement To Entitle PGA TOUR`s Western Open

Ongoing Support of Western Golf Association, Evans Scholars Expands in 2004

LEMONT, Ill.--(BUSINESS WIRE)--July 1, 2003--The PGA TOUR, Lilly ICOS LLC and the Western Golf Association (WGA) today announced that Lilly ICOS will be the title sponsor of the Western Open golf tournament beginning in 2004. The sponsorship, which will run through 2006, will also directly benefit the Evans Scholars Foundation. Additional details of the sponsorship, including the new tournament identity, will be released at a later date. Lilly ICOS is a joint venture between ICOS Corporation (Nasdaq:ICOS - News) and Eli Lilly and Company (NYSE:LLY - News).

PGA TOUR Commissioner Tim Finchem and Paul Clark, Chairman/CEO of ICOS and a member of the board of Lilly ICOS, made the announcement at Cog Hill Golf & Country Club in the Chicago area, site of this week`s 100th Western Open presented by Golf Digest.

"We`re very pleased to announce this new title sponsorship agreement. Lilly ICOS`s involvement with the Western Open reflects the importance of the PGA TOUR`s longest-running event and the Evans Scholars Foundation, which has helped more than 8,600 male and female caddies attend college since the program was established in 1930," Finchem said. "The Western Golf Association and the Western Open share a wonderful tradition of excellence and educational support. Congratulations to the WGA and Lilly ICOS."

"Lilly ICOS is delighted to have a new partner in the Western Golf Association, given its heritage, prestige and commitment to excellence," Clark said. "We know how important developing strategic partnerships can be in achieving long-term success. Selecting the right partner and being the right partner are both critical."

In addition to announcing the sponsorship, Finchem presented a $100,000 check to the Evans Scholars Foundation on behalf of the PGA TOUR in honor of the Western Open`s 100th year. The tournament first was contested in 1899, but was cancelled a total of five years, including 1943-45 due to World War II.

"We`re looking forward to a rewarding relationship with Lilly ICOS," said R.E. "Buffy" Mayerstein, Western Golf Association president. "We`re impressed with the high level of commitment shown by the leadership from Lilly ICOS to work with the Western Golf Association and the PGA TOUR in furthering the Western Open`s tradition of raising funds for our Evans Scholarships. This agreement ensures that more than 800 caddies annually will be able to continue to pursue their scholastic goals as Evans Scholars at major universities across the nation."

About the PGA TOUR

The PGA TOUR is a tax-exempt membership organization of professional golfers. Its primary purpose is to provide significant competitive earnings opportunities for past, current and future members of the PGA TOUR, Champions Tour and Nationwide Tour; to protect the integrity of the game; and to help grow the reach of the game in the U.S. and around the world.

Approximately 120 events are being contested on the three TOURs in 2003, for more than $290 million in prize money. In addition to providing competitive opportunities for its membership, TOUR events also generate significant sums of money for charity. TOUR events have raised nearly $700 million for charity since 1938, the first year such records were kept. The PGA TOUR`s Web site address is www.pgatour.com.

About Lilly ICOS

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is developing Cialis® (tadalafil) for the treatment of erectile dysfunction. Cialis is not approved for sale in the United States. A regulatory decision regarding Cialis is expected later in the second half of 2003.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and other inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

About the Western Golf Association

The Western Golf Association was founded in 1899 by 11 Chicago-area golf clubs. Today, more than 500 member clubs in states throughout the nation support the WGA, sponsor of the Western Open on the PGA TOUR and the Chick Evans Caddie Scholarships.

Headquarters for the WGA and the Evans Scholars Foundation are in Golf, Illinois, which is also home to the Glen View Club, host of the first Western Open and Western Amateur championships in 1899. In 1914, the Western Junior championship, the first such national competition in the history of American golf, was added to the WGA tournament schedule. The WGA continues to sponsor the tradition-steeped Western Open, Western Amateur and Western Junior championships.

Since 1930 the WGA also has sponsored the nationally-acclaimed Evans Scholars Foundation, which administers the nation`s largest privately funded college scholarship program. The Foundation, established by famed Chicago amateur golfer Charles "Chick" Evans Jr., has provided college educations to more than 8,600 former caddies. The Evans Scholars Foundation is the sole beneficiary of the Western Open, held at Cog Hill Golf & Country Club in Lemont, Illinois, since 1991. The annual PGA TOUR event, celebrating its 100th championship in 2003, has raised more than $32 million for the caddie scholarships in the past 73 years.

Contact:
PGA TOUR
Chris Smith, 904/273-3379
or
Lilly ICOS
Carole Copeland, 317/277-3661


Source: Lilly ICOS

[Wunram]

also auch mal wieder was zu Cialis und FDA - jetzt sind offensichtlich ausreichend Infos an die FDA geliefert worden, also hoffen wir auf eine baldige Zulassung in USA

Lilly ICOS Statement Regarding Submission to FDA of Complete Response for Cialis ``tadalafil``

BOTHELL, Wash. & INDIANAPOLIS, Ind.--(BUSINESS WIRE)--July 1, 2003--Lilly ICOS LLC disclosed today that, during the 2003 second quarter, it submitted a response to the U.S. Food and Drug Administration (FDA) of requested data on Cialis® (tadalafil), its investigational PDE5 inhibitor in development for the treatment of erectile dysfunction. Also, during the 2003 second quarter, the FDA advised Lilly ICOS that it has accepted the submission as complete. The complete response contained clinical pharmacology and other data that were requested when the FDA issued an approvable letter regarding Cialis in April 2002.

Lilly ICOS continues to expect a regulatory decision regarding Cialis late in the second half of 2003, following the FDA`s review of the complete response, approval of Lilly`s manufacturing facilities and completion of labeling discussions.

Cialis is now available in pharmacies on five continents. Since its commercial launch in Europe, in February 2003, the number of countries where the sale of Cialis has received regulatory approval has grown to approximately 35. Lilly ICOS is marketing Cialis in the European Union, and Lilly has exclusive rights to market Cialis in all other territories where the product is presently approved.

About Lilly ICOS

Lilly ICOS, a joint venture between ICOS Corporation (Nasdaq:ICOS - News) and Eli Lilly and Company (NYSE:LLY - News), is developing Cialis, a PDE5 inhibitor, in the European Union and North America for the treatment of erectile dysfunction.

About Lilly

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

About ICOS

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, and sepsis and other inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

Certain of the matters discussed herein with respect to clinical studies and commercial plans for ICOS and Lilly`s products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that PDE5 inhibitors developed by Lilly ICOS will receive regulatory approvals or achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. The companies undertake no duty to update forward-looking statements.

Contact:
Lilly
Carole Copeland, 317/277-3661
or
ICOS
Lacy Fitzpatrick, 425/415-2207

Source: Lilly ICOS LLC

[kurttilly]

Hallo Icos-Fans!

Kennt jemand schon die neuesten Zahlen???

Danke im Voraus!

kurttilly

[Wunram]

ja - 19ct/share Verlust gegenüber 66ct/share im gleichen Quartal 2002. Nachbörslich -6,5%

[KMS]

Oha, ICOS -16 % an der Nasdaq (33,15 $).
Warum dieser Ausverkauf?
Waren die Zahlen so schlecht?

KMS

[meislo]

http://62.146.24.165/news.php?show=129566

[Wunram]

mal wieder was neues zu Cialis

New Data From Lilly ICOS Describe Efficacy of Cialis in Difficult-to-Treat Prostatectomy Patients

10 October 2003, 08:00am ET

BOTHELL, Wash. & INDIANAPOLIS--(BUSINESS WIRE)--Oct. 10, 2003--

Additional Analyses Highlight Sexual Attempts at Various
Time Intervals and Cialis Efficacy After First Dose
Among new clinical data on Cialis(R) (tadalafil) presented this weekend, 62 percent of men who underwent bilateral nerve-sparing radical retropubic prostatectomy (BNSRRP), a surgery for prostate cancer, reported improved erections after taking the drug. Experts have said that more than half of men report erectile dysfunction (ED) 18 months or more after this form of radical prostatectomy(1), which is among difficult to treat causes of the condition.

"Despite numerous advances in prostatectomy technique, data suggest that localized nerve trauma leaves many men with ED that is quite challenging to manage," said Joel Kaufman, M.D., Medical Director of Urology Research Options, Aurora, Colo. "In this trial, men taking Cialis reported an improvement in measures of improved erections, and maintaining erections for both penetration and completion of intercourse."

Cialis is a new investigational PDE5 inhibitor being developed by Lilly ICOS LLC (Lilly ICOS) for the treatment of ED. This weekend, several abstracts on Cialis will be formally presented at the annual meeting of the Sexual Medicine Society in Denver.

Other findings announced this weekend include:

-- 82 percent of men in an analysis of clinical trials attempted
intercourse at least once between four hours and up to 36
hours after taking the drug over a 12 week period

-- Up to 67 percent of men with ED in another set of clinical
trials reported they were able to have successful intercourse
after taking Cialis for the first time.

Cialis Efficacy in BNSRRP Patients
The study demonstrated that 62 percent of men who developed ED following BNSRRP, a surgery for prostate cancer, reported improved erections after taking Cialis 20mg, compared to 23 percent with placebo, based on the question of whether the treatment they were taking improved their erections.

-- Patients recorded that a majority of sexual attempts (54
percent) by men who took Cialis resulted in successful vaginal
penetration as compared to 32 percent on placebo (p less than
0.001).

-- In a subgroup of men (N=201) who were able to experience some
erection following this type of radical prostatectomy, 71
percent experienced an improved erection compared to 24
percent on placebo (p less than 0.001).

-- The most commonly reported (greater than or equal to 5
percent) treatment-emergent adverse events with Cialis in the
study were headache, upset stomach, and muscle ache.
This Phase III multi-center study consisted of a four-week treatment-free period followed by 12 weeks of treatment with Cialis 20mg or placebo. In the study, 303 men who had undergone bilateral nerve sparing radical prostatectomy 12-48 months pre-study were randomized (2:1) to Cialis 20mg or placebo. The study included a subgroup of 201 men who still retained the ability to have some erection following this type of surgery.

Time Distribution of Sexual Intercourse Attempts with Cialis

In an analysis of studies assessing the time distribution of intercourse attempts by men with ED after taking Cialis:

-- 82 percent of men attempted intercourse at least once between
four and 36 hours after taking Cialis 10mg or Cialis 20mg over
a 12-week period. The pattern of attempts was similar in the
placebo group.
These data were compiled from 11 randomized, double-blind placebo controlled 12-week efficacy studies evaluating 2,102 men with ED taking Cialis 10mg, 20mg, or placebo. Medication was taken prior to sexual activity without restriction to timing of subsequent sexual intercourse attempts. In the studies, among the most commonly reported side effects reported were headache, upset stomach, backache, and muscle ache.

Early Treatment Success with Cialis
In a retrospective analysis of data from five clinical trials among a broad population of 887 men with ED assessing intercourse after the first dose taken, 67 percent of men who took Cialis 20mg and 56 percent of men who took Cialis 10mg experienced successful intercourse with their very first dose, both compared to 31 percent for the placebo group (p less than 0.001).

-- After the first four doses, 86 percent of men who took Cialis
20mg and 72 percent of men who took Cialis 10mg achieved
successful intercourse for the first time compared to 48
percent of men on placebo (p less than 0.001).

-- Among those men who had a successful intercourse attempt with
their first dose, 88 percent of subsequent intercourse
attempts were successful for those who took Cialis 20mg and 81
percent of those who took Cialis 10mg over the 12-week
treatment period. Both compared to 64 percent in the placebo
group (p less than 0.001).
These data were compiled from five double blind placebo-controlled studies with 12-weeks of treatment with Cialis or placebo in men with ED. Patients were instructed to take Cialis prior to sexual activity and without regard to food. In the studies, among the most commonly reported side effects reported were headache, upset stomach, backache, and muscle ache.

About Cialis

Lilly ICOS received an approvable letter for Cialis from the U.S. Food and Drug Administration in April 2002 and anticipates a U.S. regulatory decision for Cialis late in 2003. Cialis is for sale in more than 40 countries, including countries in Europe and in Australia, Brazil, Mexico, Russia, and Saudi Arabia.

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. Up to 80 percent of ED cases are caused by physiological conditions, including cardiovascular disease and diabetes, with psychological factors accounting for the remaining 20 percent. In many cases, however, both psychological and physiological factors contribute to the condition.(2)

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is developing Cialis for the treatment of erectile dysfunction.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

Certain of the matters discussed herein with respect to clinical studies and commercial plans for ICOS and Lilly`s products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will receive regulatory approvals as expected or achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. The companies undertake no duty to update forward-looking statements.

(1) Stanford, et. al. JAMA Vol. 283, No. 3. January 19, 2000

(2) Impotency Information from NIH. NIH Publication No. 95-3923.1995.

CONTACT: Lilly
Nicole Hebert, 317-277-6990
or
ICOS
Lacy Fitzpatrick, 425-415-2207

SOURCE: Lilly ICOS LLC


ob das in 2003 noch was wird mit der FDA-Zulassung??

[Wunram]

nicht schlecht - an so einem Tag +7%! Annähernd 52-Wochen Hoch. Stehen Neuigkeiten vor der Tür??

[CaptainBlaubär]

Fast geschafft

CB

[JohannesBoos]

ich sag euch, der Kurs wir bald bei mindestens 55 $ stehen, wenn die Pille in den USA zugelassen wird! Und das soll noch dieses Jahr passieren! Also eigentlich ein klarer Kauf, wie auch bei Börse Online, die fast alle 3 Wochen auf diesen wert hinweisen!

[Wunram]

intereessiert es keinen mehr??

ICOS Corp 3Q Loss 63 Cents/Share


BOTHELL, Wash. -(Dow Jones)- Icos Corp.(NASDAQ-NMS:ICOS) (ICOS) posted a wider third-quarter loss as revenue fell by nearly half.

The biotech company said in a press release Tuesday that its loss was $39.3 million, or 63 cents a share, compared with a loss of $34.5 million, or 56 cents a share, a year earlier.

The reported loss wasn`t as steep as the 80 cents a share Wall Street had been expecting, according to Thomson First Call, which polled about a dozen analysts.

Overall revenue fell 46% to $12.1 million from $22.2 million in the period last year as cost-reimbursement revenue, which the company describes as collaborative revenue from affiliates, plunged 70% to $5.34 million.

Analysts, on average, expected Icos` overall top line to fall to $6.07 million.

The company saw research and development spending fall 28% to $24.6 million, while overall operating costs decreased 9% to $34.9 million.

Marketing costs increased due to Icos` focus on Cialis, which is expected to win approval by the Food and Drug Administration soon as a treatment for erectile dysfunction in the U.S. Cialis is made by Lilly ICOS LLC(NASDAQ-NMS:ICOS) , a joint venture with Eli Lilly & Co.(NYSE:LLY) (LLY), and has been on the market in some European countries for nearly a year.

Icos said that following the February launch of Cialis in Europe, worldwide sales continued to climb, surpassing $100 million in September.

If approved in the U.S., the drug will compete with Pfizer Inc.(NYSE:PFE) `s (PFE) Viagra, and also Levitra, which is made by GlaxoSmithKline PLC(NYSE:GSK) (GSK) and Bayer AG(NYSE:BAY) (BAY). Cialis can last more than four times as long as Viagra or Levitra, up to 36 hours. The drug won approval in Mexico in August and in Canada in September.

Icos` marketing and selling expenses jumped to $8.21 million from $1.68 million a year earlier as the company helped bankroll establishment of a U.S. sales force for Cialis.

Icos` 50% share of Lilly Icos` losses increased $3.7 million to $16.9 million.

The company said the drop in collaboration revenue from affiliates reflected a move in December to end development activities on the drug Pafase. The loss was partly offset by higher cost-reimbursement revenue from Lilly Icos.

Icos said its contract-manufacturing revenue more than doubled to $6.8 million.

Icos Corp.(NASDAQ-NMS:ICOS)
- Bothell, Wash.
3rd Quar Sept. 30:
2003 2002
Revenue $12,103,000 $22,210,000
Net income (39,309,000) (34,531,000)
Avg shrs 62,717,000 61,980,000
Shr earns
Net income (.63) (.56)
Figures in parentheses are losses.

Company Web site: http://www.icos.com

-Tim Paradis; Dow Jones Newswires; 201-938-5400


Dow Jones Newswires
11-04-031620ETCopyright (C) 2003 Dow Jones & Company, Inc. All Rights Reserved.

Wer das ganze 10-Q filing lesen will
http://www.edgar-online.com/bin/cobrand/finSys_main.asp?nad=…

Wunram

[Wunram]

Golfprofis mit Erektionsproblemen??? Geld scheint man ja zu haben bei ICOS!

The PGA TOUR and Lilly ICOS Announce Multi-Year Partnership

New Western Open Sponsor Introduces Broadcast Vignette Program and Co-Sponsored Scoreboards

HOUSTON--(BUSINESS WIRE)--Nov. 5, 2003--Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq:ICOS - News) and Eli Lilly and Company (NYSE:LLY - News), today has entered into a four-year sponsorship agreement with the PGA TOUR. Lilly ICOS becomes an official partner of both the PGA TOUR and Champions Tour beginning in 2004. The joint announcement was made today at Champions Golf Club in Houston, site of this week`s THE TOUR Championship presented by Coca-Cola®.

To support the partnership, the PGA TOUR and Lilly ICOS are developing a series of golf-themed vignettes featuring top players from both Tours. The vignettes will focus primarily on the emotional connection to the game with themes such as relaxation, preparation and confidence. The motivational vignettes will air during PGA TOUR telecasts throughout 2004 and will be featured on PGATOUR.COM. The agreement also includes an on-site component, whereby Lilly ICOS will join MasterCard® as a sponsor of the electronic scoreboards at PGA TOUR and Champions Tour events. As such, it will receive a dedicated ad panel on each scoreboard. Lilly ICOS will also have the right to use the PGA TOUR logo in advertising.

Lilly ICOS, which was introduced as the new title sponsor of the Western Open on July 1, 2003, is also developing an integrated program to further support its connection to golf and leverage its association with the PGA TOUR. These plans will be announced at a later date.

"We are extremely pleased that such an outstanding company has expanded its involvement with the TOUR through a marketing relationship, just four months after agreeing to become the title sponsor of the Western Open," said Tom Wade, the PGA TOUR`s Chief Marketing Officer. "We have been working together for well over a year to develop an integrated marketing platform which we`re confident will provide value to both Lilly ICOS and the PGA TOUR."

"Lilly ICOS is delighted to join the PGA TOUR family as an official partner," said Paul Clark, Chairman and Chief Executive Officer of ICOS and a member of the Lilly ICOS board. "Those who watch and play golf are an important audience for us. A partnership with the PGA TOUR allows us to connect with millions of golf fans, many of whom enjoy golf because it is both relaxing and invigorating."

About the PGA TOUR

The PGA TOUR is a tax-exempt membership organization of professional golfers. Its primary purpose is to provide significant competitive earnings opportunities for past, current and future members of the PGA TOUR, Champions Tour and Nationwide Tour; to protect the integrity of the game; and to help grow the reach of the game in the U.S. and around the world.

Approximately 120 events are being contested on the three Tours in 2003, for more than $290 million in prize money. In addition to providing competitive opportunities for its membership, TOUR events also generate significant sums of money for charity. TOUR events have raised more than $750 million for charity since 1938, the first year such records were kept. The PGA TOUR`s Web site address is www.pgatour.com.

About Lilly ICOS

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, is developing Cialis® (tadalafil) for the treatment of erectile dysfunction. Lilly ICOS received an approvable letter for Cialis from the U.S. Food and Drug Administration in April 2002 and anticipates approval of Cialis late in 2003. Cialis is approved for sale in more than 45 countries, including countries in Europe and in Australia, Brazil, Mexico, Russia, and Saudi Arabia.

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world`s most urgent medical needs.

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and other inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

Forward-Looking Statement

Certain of the matters discussed herein with respect to clinical studies and commercial plans for ICOS and Lilly`s products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will receive regulatory approvals as expected or achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. The companies undertake no duty to update forward-looking statements.

Contact:
PGA Tour
Chris Smith, 904-273-3379
or
Lilly ICOS
Carole Copeland, 317-277-3661

Source: Lilly ICOS

[Wunram]

ja - sogar noch im November 2003!

Lilly ICOS Announces FDA Approval of Cialis -tadalafil-

21 November 2003, 12:31pm ET

BOTHELL, Wash. & INDIANAPOLIS--(BUSINESS WIRE)--Nov. 21, 2003--Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS) today has received the approval letter for Cialis(R) from the Food and Drug Administration. Further information will be forthcoming from Lilly ICOS.

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, was formed to develop and market Cialis.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world`s most urgent medical needs. Additional information about Lilly is available at www.lilly.com .

Mentioned Last Change
ICOS 43.39 1.64dollars or (3.64%)
LLY 69.80 1.73dollars or (2.41%)
ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

Certain of the matters discussed herein with respect to clinical studies and commercial plans for ICOS and Lilly`s products may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will receive additional regulatory approvals as expected or achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. The companies undertake no duty to update forward-looking statements.

CONTACT: Media Refer to:
Lilly
Carole Copeland, 317-277-3661
or
Investor Relations:
ICOS
Lacy Fitzpatrick, 425-415-2207

SOURCE: Lilly ICOS

[Wunram]

mit ein bisschen mehr Text

Lilly ICOS Announces FDA Approval of Cialis -- tadalafil -- A New OralTreatment for Erectile Dysfunction

BOTHELL, Wash. & INDIANAPOLIS, Nov 21, 2003 (BUSINESS WIRE) -- Lilly ICOS LLC (NYSE:LLY)(Nasdaq:ICOS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cialis(R) (tadalafil), a new oral PDE5 inhibitor, for the treatment of erectile dysfunction (ED). Cialis (pronounced see-AL-iss) was shown to improve erectile function compared to placebo up to 36 hours following dosing. In clinical studies, the ability to have sexual activity was improved in some patients at 30 minutes after taking a dose. Cialis will be available in pharmacies in early December.

"Cialis is an exciting new option for men with ED," said Dr. Francois Eid, Clinical Associate Professor of Urology, Weill Cornell Medical College. "Because Cialis works for up to 36 hours, it provides a man and his partner substantial freedom to choose the moment that is right for intimacy. With Cialis, the need for planning intimacy may be reduced."

The safety and efficacy of Cialis was evaluated in 22 clinical trials in more than 4,000 patients. Cialis was shown to be effective in treating ED in patients 27 to 87 years old, including patients with other underlying medical conditions. In two of these trials, men had ED associated with diabetes or following radical prostatectomy for prostate cancer.

"Cialis is a new treatment option for erectile dysfunction that will be available for men in the United States," said Sidney Taurel, chairman and chief executive officer of Eli Lilly and Company. "Erectile dysfunction is a significant medical condition that affects millions of men in the U.S. Men tell us they want an ED treatment that will reduce the constraints of planning and allow them to choose the moment that is right for intimacy."

"Cialis is now available in approximately 50 countries and has been used by more than one million men worldwide, " said Paul Clark, ICOS chairman and chief executive officer. "The early success of Cialis in other markets makes us confident that American men and their partners will appreciate this new treatment option."

Safety Profile

Cialis is not for everyone. Men taking any form of nitrates (often used to control anginal chest pain) should never take Cialis, as the combination may cause an unsafe drop in blood pressure. Men taking medicines called "alpha blockers" (sometimes prescribed for prostate problems or high blood pressure), with the exception of Flomax(R)(1)(tamsulosin HCl) 0.4 mg once-daily, should not take Cialis. This combination could also cause a significant drop in blood pressure.

In clinical trials, the most common side effects with Cialis were headache, upset stomach, backache, and muscle ache. Most men weren`t bothered by the side effects enough to stop taking Cialis. In placebo controlled Phase III clinical trials, discontinuation rates in patients treated with Cialis 10 mg or 20 mg was 3.1%, compared to 1.4% in placebo treated patients. Cialis is not recommended in patients who have suffered a heart attack or stroke within the last six months, or patients who have significantly low blood pressure, uncontrolled high blood pressure, unstable angina, severe liver impairment, or retinitis pigmentosa (a rare eye disorder). Men should discuss their health status with their doctors to ensure that Cialis is right for them and that they are healthy enough to engage in sexual activity. Cialis does not protect a man or his partner from sexually transmitted diseases, including HIV.

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse.(2) It is believed that 85 - 90 percent of ED cases are related to a physical or medical condition, like diabetes or cardiovascular disease, while 10 - 15 percent are due to psychological causes.(3) In many cases a combination of both contribute to ED.

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, was formed to develop and market Cialis.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world`s most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com .

ICOS Corporation is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and inflammatory diseases. ICOS` strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS` opportunities to market breakthrough products.

For full prescribing information, visit http://www.cialis.com funktioniert derzeit nicht.

Certain of the matters discussed herein may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies. More specifically, there can be no assurance that this product will achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. The companies undertake no duty to update forward-looking statements.


(1) Flomax(R) is a registered trademark of Boehringer Ingelheim

(2) NIH Consensus Development Panel on Impotence. NIH Consensus
Conference. Impotence. JAMA. 1993:270:83-90.

(3) Diseases and Conditions: Impotence,
www.impotence.org/FAQ/index.asp. Accessed on November
19, 2003

Note: Photos available at URLs:

www.businesswire.com/cgi-bin/photo.cgi?pw.112103/bb6

www.businesswire.com/cgi-bin/photo.cgi?pw.112103/bb6a

SOURCE: Lilly ICOS LLC


CONTACT: Lilly
Carole Copeland, 317-277-3661
ICOS
Lacy Fitzpatrick, 425-415-2207

[JohannesBoos]

Keiner aus Deutschland mehr an ICOS inetressiert???

[Snoopy28]

Hallo, weiß jemand warum ICOS nur noch fällt??

Wann ist denn die (voraussichtliche) Zulassung in den USA.
In Europa gewinnt die Aktie ja in allen Ländern massiv Marktanteile, kann das eigentlich gerade nicht verstehen.

Wer von Euch weiß was??

[JohannesBoos]

Ja, ganz verstehen kann ich das auch nich!!!
Bald sollte die Zulassung mal kommen! Das Einzige was ich für den Kursverlauf verantwortlich machen kann, ist, dass die Aktie, glaub ich, nicht mehr im Nasdaq 100 gelistet ist. Was meinst du?

[Wunram]

Bathtub scene to kick off Cialis U.S. ad campaign

16 January 2004, 2:20pm ET

By Bill Berkrot

NEW YORK, Jan 16 (Reuters) - The battle for Viagra`s turf is about to escalate when Cialis, the impotence treatment with the staying power that has seen it dubbed "le weekend" in Europe, kicks off its first U.S. ad campaign during Sunday`s NFL conference championship games.

But the opening salvo by the third major entry into the multibillion-dollar erectile dysfunction (ED) market from Eli Lilly & Co. (NYSE:LLY) and Icos Corp. (NASDAQ:ICOS) will be an exceedingly quiet, not to mention, squeaky clean one.

The 15-second spot features a couple in side-by-side bathtubs on a bluff as the sun sets into the sea before them, bathing the entire scene in a golden glow.

As the woman languidly reaches her hand across toward her partner`s, a voice over mellow jazz guitar says: "Cialis is here. Are you ready?"

"We consider this a big, big event," Matt Beebe, the U.S. brand team leader for Cialis, told Reuters.

"We have been working with healthcare professionals and doctors for a couple months now since approval. It is time now to go to the general population.

"The distribution channels are completely filled, so the time is perfect to start the awareness campaign," Beebe said.

Mentioned Last Change
ICOS 40.45 1.15dollars or (2.92%)
LLY 70.01 0.50dollars or (0.71%)
PFE 34.94 0.12dollars or (0.34%)
Many industry observers feel Cialis will emerge as serious competition for Viagra, which boasts annual sales of $1.7 billion. But analysts and the drugmakers also believe the ED market could expand to several times its current size, leaving room for healthy profit for all who participate.

Late last year, Cialis followed Levitra from GlaxoSmithKline (LSE:GSK) and Bayer AG (DE:BAYG) into the market created by Pfizer Inc.`s (NYSE:PFE) famous blue pill.

Cialis is fast gaining a foothold in Europe, where its ability to work for up to 36 hours -- about nine times the average window of effectiveness of Viagra -- has distinguished it from its rivals.

Although, competing with a Viagra`s five-year head start and phenomenal name recognition is a daunting task, Lilly believes Pfizer blazed a trail for the newcomers.

"Cialis is coming into a marketplace that is educated and that still has a lot of room to grow," Beebe said.

Longer commercials to be unveiled throughout the year will highlight Cialis`s duration advantage and the opportunity for spontaneity it affords, Beebe said.

The company declined to divulge the advertising budget for Cialis, but Beebe said it will be very competitive.

"We are going to have a major presence in the media in the U.S. market with TV, print, radio and outdoor advertising," he said.

That starts in earnest on Sunday with an NFL audience coveted by all companies looking to reach adult males.

According to advertising trade reports, all three ED drugs will air commercials during the Feb. 1 Super Bowl, where media buyers say a 30-second spot will cost more than $2 million.

Lilly and its ad agency, Grey Worldwide, decided to eschew the celebrity athlete endorsements favored by Viagra. They said they will also avoid the not-so-subliminal suggestive images, such as footballs going through swinging tires, featured in Levitra`s "get back in the game" campaign.

Instead, they plan to show couples in scenes that suggest no urgent time constraints or pressure to perform.

"It gives you the feel of something relaxed," Beebe said of the bathtubs spot. "A tender moment could turn into the right moment."

[Lifetrader]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Wunram]

mal wieder ein Lebenszeichen von ICOS




Lilly ICOS` Cialis(R) (tadalafil) Makes Impressive Strides in First Six Months on the U.S. ED Treatment Market

- Cialis Leads Market in New Treatment Initiations by Urologists and Switches for April -

BOTHELL, Wash. and INDIANAPOLIS, June 2 /PRNewswire-FirstCall/ -- After only six months, Cialis® (tadalafil),(1) the latest oral erectile dysfunction (ED) treatment on the market in the U.S., is challenging Viagra® (sildenafil citrate)(2) for share of the ED market as Cialis leads in new treatment initiations by urologists(3) and switches from other products for April. Cialis is marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company (NYSE: LLY - News) and ICOS Corporation (Nasdaq: ICOS - News). Cialis is the only ED treatment shown to improve erectile function up to 36 hours in most men. Cialis can be taken without regard to food.
Cialis Leads in New Treatment Initiations

According to market research firm ImpactRx(TM) (which tracks the habits of a panel of high prescribing physicians and may reflect emerging trends in doctors` offices today),(4) U.S. urologists initiated treatment with Cialis in April at a rate of more than two-to-one over each of the other oral ED treatments. In fact, Cialis represented 56 percent of new treatment initiations by urologists in April, compared to 21 percent for Levitra® (vardenafil HCl)(5) and 23 percent for Viagra.(6)
Based on data from IMS, another source of market information, in April, Cialis represented 30 percent of new ED treatment prescriptions written by urologists, compared to 16 percent for Levitra and 54 percent for Viagra.(7)

Cialis Leads in Switches

In April, nearly two thirds of all men who switched their oral ED treatment switched to Cialis. Following is information from ImpactRx on share of new prescriptions written in April by doctors changing their patients` ED treatment from one product to another:

Primary Care Physicians Urologists
Cialis 60% 69%
Levitra 36% 26%
Viagra 4% 5%

In an independent clinical study, more men selected Cialis as their preferred treatment of choice after trying different oral ED medications, primarily because of how long the drug worked.(8) This may explain why many men with ED who are on oral treatment are switching to Cialis.

Cialis Challenges Viagra

The percentages of new prescriptions written by all doctors for oral ED treatments in April broke out as follows: Cialis, 19 percent; Levitra, 14 percent; and Viagra, 67 percent.(9) "The early success of Cialis in the U.S. is similar to the trend we saw when it first became available in other countries. Cialis has claimed market shares of 19 percent to 39 percent across Europe, and even higher in some other markets," said Leonard Blum, vice president of marketing, ICOS Corporation. In the first quarter of 2004, Cialis achieved $108 million in global sales. More than two million men around the world have been treated with Cialis since its first introduction globally last year.

"For us, the number of Cialis prescriptions written by urologists is one of the most important indicators of future trends. Urologists are the experts in treating ED. We expected that urologists would be the quickest adopters of Cialis, and the data suggest that these specialists, like their peers overseas, are making Cialis their preferred treatment," said Blum.

Benefits of Cialis

Cialis is changing the way doctors and patients think about treating ED by offering two important benefits: a 36-hour window of opportunity for intimacy and the ability to take the tablet on an empty stomach or with a meal, without concern that high-fat food will reduce the absorption of the medicine.

"What the marketplace tells us is that men and their partners are truly taking advantage of the benefits of Cialis," said Matt Beebe, U.S. brand team leader for Cialis, Lilly ICOS LLC. "Men can take Cialis Friday evening and choose the moment for romance as late as Sunday morning. Because Cialis works for up to 36 hours, it allows a man and his partner to relax, forget about planning intimacy and let it happen when the moment is right for them."

About Cialis

Cialis, approved by the FDA in November 2003 for the treatment of erectile dysfunction, is the only oral ED treatment shown to improve erectile function up to 36 hours in most men. Cialis can be taken without regard to food. The absorption of Cialis is not reduced by food, including high-fat foods. Cialis is currently available in more than 60 countries, including Australia, Brazil, Mexico, Canada, the United States and countries throughout Europe. More than two million patients worldwide have been treated with Cialis since its first introduction in February 2003.

Cialis is available by prescription only and is not for everyone. Men taking nitrates, often used for chest pain, or certain alpha-blockers for prostate problems or high blood pressure, should not take Cialis. Such combinations could cause a sudden, unsafe drop in blood pressure.

Men should discuss their health status with their doctors to ensure Cialis is right for them and that they are healthy enough for sexual activity.

The most common side effects with Cialis were headache, upset stomach, delayed backache and muscle ache. Although rare, men who experience an erection for more than four hours should seek immediate medical attention. Men should not drink alcohol in excess with Cialis. Cialis studies were not designed to assess multiple intercourse attempts after a single dose.

For full patient information, visit www.cialis.com .

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. ED affects an estimated 152 million men and their partners worldwide.(10) Experts believe that 80 - 90 percent of ED cases are related to a physical or medical condition, like diabetes, cardiovascular diseases, and prostate cancer treatment, while 10 - 20 percent are due to psychological causes.(11,12) In many cases, however, both psychological and physiological factors contribute to the condition.(13)

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, developed tadalafil for the treatment of erectile dysfunction.

Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs. Additional information about Lilly is available at www.lilly.com .

ICOS Corporation, a biotechnology company, is dedicated to bringing innovative therapeutics to patients. Headquartered in Bothell, Washington, ICOS is marketing its first product, Cialis® (tadalafil), for the treatment of erectile dysfunction. ICOS is working to develop treatments for serious unmet medical conditions such as chronic obstructive pulmonary disease, cancer and inflammatory diseases.

B-roll is available via satellite, C-band feed:
WEDNESDAY, JUNE 2, 10:30 - 11:00 AM EDT C-Band, IA 6, Tr. 21, DL 4120
WEDNESDAY, JUNE 2, 13:15 - 13:45 PM EDT C-Band, IA 5, Tr. 23, DL 4160
THURSDAY, JUNE 3, 13:00 - 13:30 PM EDT C-Band, IA 5, Tr. 14, DL 3980

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by the management of ICOS and Lilly. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological, legal and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies and Lilly ICOS. Results and the timing and outcome of events may differ materially from those expressed or implied by the forward-looking statements in this press release. More specifically, there can be no assurance that Cialis will achieve commercial success or that competing products will not pre-empt market opportunities that might exist for the product.

(1) Cialis® is a registered trademark of Lilly ICOS LLC. All other trademarks are the property of their respective owners.
(2) Viagra® is a registered trademark of Pfizer, Inc.
(3) The term "new treatment initiations" indicates when a physician writes out a new prescription for patients never before treated, and for patients switching from one product to another. This does not include prescriptions conveyed to pharmacies by phone or refills of existing prescriptions. In this release, new treatment initiations describe data from ImpactRx only.
(4) ImpactRx(TM) has a panel of high prescribing physicians that recorded information on patient visits (patient identity is non-identifiable), including diagnosis and treatment. ImpactRx data includes new prescriptions written and refills but not prescriptions conveyed by phone. ImpactRx records information from the physician perspective and not what happens at the pharmacy.
(5) Levitra® is a registered trademark of Bayer/GSK.
(6) ImpactRx, "PromoLink," April 2004.
(7) Computed from IMS NPA Plus(TM), April 2004. IMS numbers vary from those of ImpactRx primarily because IMS data represent aggregated pharmacy sales, reflecting what is filled at the pharmacy including new prescriptions for continuing users and prescriptions called in by phone.
(8) "The Three PDE 5 Inhibitors Sildenafil, Tadalafil And Vardenafil - Results Of A Comparative Preference Trial In 222 Patients With Erectile Dysfunction," Hartmut Porst, et. al., presented in poster session at American Urological Association Annual Meeting, May 2004.
(9) Computed from IMS NPA Plus(TM), April 2004.
(10) Aytac Ia, McKinlay JB, Krane RJ. The Likely Worldwide Increase in Erectile Dysfunction Between 1995 and 2025 and Some Possible Policy Consequences. BJU Int 1999; 84: 50-56.
(11) Shabsigh, R. (2002). Back To Great Sex: Overcome ED and Reclaim Lost Intimacy. New York: Kensington.
(12) Diseases and Conditions: Impotence, http://www.impotence.org/FAQ/index.asp . Data accessed 11.20.03
(13) Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-1813



---------------------
Source: Lilly ICOS LLC


Gruss Wunram

[Wunram]

ICOS glaubt an Cialis

Lilly ICOS Offers "Cialis Promise" Program to Men with ED - Pays for a Competing Product if They are Not Satisfied

In a first for the pharmaceutical industry, Lilly ICOS LLC, maker of Cialis® (tadalafil), is committing to pay for a competing erectile dysfunction (ED) product if men are not satisfied with Cialis. Through a limited-time special offer called "The Cialis Promise," men with ED who have never used Cialis can receive a voucher for a free trial. If they like Cialis, they can get a second trial at no charge. If they are not satisfied with Cialis, Lilly ICOS will pay for a trial of a competing oral ED product as prescribed by their doctor.

The Cialis Promise launches nationwide today through a print and broadcast ad campaign that features a twist on the signature Cialis advertising image of a couple watching a sunset while seated in side-by-side bathtubs. This time, the bathtubs are empty and the tagline reads, "Looks Like Someone Discovered The Cialis Promise." Cialis is the only oral ED treatment clinically proven to both act fast and work up to 36 hours for most men. In addition, Cialis can be taken without regard to food. These benefits allow a man and his partner to relax and let intimacy happen when the moment is right for them.

"We are so confident that men with ED will appreciate the benefits of Cialis that we`re willing to go as far as offering to pay for our competitors` products if they are not satisfied," said Paul Clark, chairman and CEO of ICOS Corporation. "Because Cialis provides a broad window of opportunity to choose the moment that`s right for a man and his partner, we believe that most men will be satisfied with their experience with Cialis, and will want to stick with it beyond the free trial."

How The Cialis Promise Works

Men with ED can download a free Cialis voucher and the Cialis Promise Card from the Cialis Web site, www.cialis.com. A man would then talk to his doctor to determine if Cialis is right for him. If his doctor writes him a prescription for Cialis, he would take it and the free Cialis voucher to his local pharmacy to get a free trial. After taking Cialis as directed by his doctor, the man would fill out the Cialis Promise Card and send it, along with a copy of his pharmacy receipt from the free voucher to:

CIALIS PROMISE

P.O. Box 4846

Trenton, NJ 08650

If he decides that Cialis is the treatment for him, Lilly ICOS will send him another voucher for an additional sample of Cialis tablets, as prescribed by his doctor. If he is not satisfied with Cialis, the company will send him a voucher for a trial of the oral ED treatment (PDE5 inhibitor) of his choice, as prescribed by his doctor. The Cialis Promise is a limited time offer, and Lilly ICOS reserves the right to end the promotion at any time. Men should note: only a doctor or other healthcare professional can determine if an ED medication is right for an individual patient.

What 36 Hours Means for Men with ED

Treating ED is about more than helping a man achieve an erection, according to noted sexologist Marian E. Dunn, Ph.D., clinical associate professor and director of the Center for Human Sexuality, department of Psychiatry, State University of New York, Health Science Center, Brooklyn.

"Today, my patients tell me they want a treatment that allows them spontaneity in their relationship and time to connect as a couple," said Dunn. "Men who have ED already feel a great deal of pressure from their condition and from the need to plan intimacy. So men and their partners want a treatment option that will reduce time pressure."

A recent survey of 300 current Cialis users supports Dunn`s conclusion and provides insight on why many men with ED are choosing Cialis. According to the survey results, more than 80 percent of respondents indicated that intimacy was best when there are no time constraints and when there is no need to plan the moment aside from taking the pill. Further, 77 percent of men surveyed indicated that with Cialis, they didn`t have to worry about being intimate within a certain period of time.1

About Cialis

Cialis, approved by the FDA in November 2003 for the treatment of erectile dysfunction, is the only oral ED treatment shown to improve erectile function up to 36 hours in most men. Cialis can be taken without regard to food. The absorption of Cialis is not reduced by food, including high-fat foods. Cialis is currently available in approximately 70 countries, including Australia, Brazil, Mexico, Canada, the United States and countries throughout Europe. More than two million patients worldwide have been treated with Cialis since its first introduction in February 2003.

Cialis is available by prescription only and is not for everyone. Men taking nitrates, often used for chest pain, or certain alpha-blockers for prostate problems or high blood pressure, should not take Cialis. Such combinations could cause a sudden, unsafe drop in blood pressure.

Men should discuss their health status with their doctors to ensure Cialis is right for them and that they are healthy enough for sexual activity.

The most common side effects with Cialis were headache, upset stomach, delayed backache and muscle ache. Although rare, men who experience an erection for more than four hours should seek immediate medical attention. Men should not drink alcohol in excess with Cialis. Cialis studies were not designed to assess multiple intercourse attempts after a single dose.

For full patient information, visit www.cialis.com.

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. ED affects an estimated 152 million men and their partners worldwide.2 Experts believe that 80 - 90 percent of ED cases are related to a physical or medical condition, like diabetes, cardiovascular diseases, and prostate cancer treatment, while 10 - 20 percent are due to psychological causes.3,4 In many cases, however, both psychological and physical factors contribute to the condition.5

About Lilly ICOS LLC ......

[Wunram]

Cialis Absatz steigt

Umsatz steigt

Verluste leider auch

alles weiter hier:

Thread: Kein Titel für Thread 4100594870

Gruss Wunram

[kurttilly]

Es gibt noch ICOS - Interessierte!!!!



Auf deutsch:
BOSTON (AFX) -- Cialis Hersteller Icos sah seinen auf lagersprung fast 5 Prozent Montag auf Nachrichten, denen die Droge jetzt ungefähr 17 Prozent des Marktes für aufrichtbare Funktionsstörungdrogen übernommen hatte. Anteile von Icos waren herauf 4.78 Prozent bei dem $24.33 Montag Nachmittag. Der company`s Marketing-Partner für Cialis, Eli Lilly, Säge seine Anteile verlieren 1.72 Prozent bis $53.81. Nach Ansicht SG Cowen des Analytikers Philip Nadeau, Icos verschob sich groß auf Nachrichten, die die industry`s meisten neuen Verordnungdaten zeigten, daß Zahl der Verordnungen, die für Cialis herausgegeben wurden, 17 Prozent, vierteln Überviertel erhöht hatte. Im Vergleich sagte Nadeau, zeigten die Daten, daß Verordnungen von Pfizer`s Viagra 3 Prozent geglitten hatten, während Levitra nur gesehen einer 1-Prozent-Zunahme gesehen hatte. Levitra wird von GlaxoSmithKline und von Bayer vermarktet. Nadeau schrieb die Daten IMS Gesundheit, eine Forschungsgruppe zu, die pharmazeutische Verkäufe und Verordnungdaten für die Industrie aufspürt. "The IMS Verordnungdaten schauten besser als die anderer Konkurrenten in der Kategorie, " der Analytiker gesagt. "Cialis` Daten waren groß in der Linie, möglicherweise ein kleines oben genanntes, was wir expecting." waren; Er addierte, daß die neuesten Daten auch zu den Investoren, daß 2004 Verkäufe der Droge wahrscheinlich jetzt an der oberen Strecke der Prognose beenden, gegeben durch Icos und Lilly, von $500 Million bis $600 Million signalisieren. das gesagte "That, Viagra hat noch mehr als zweidrittel des Marktes. They`re, das noch wütend, " konkurriert; ausgearbeittes Nadeau. SG Cowen erwartet Cialis, um ungefähr 30 Prozent des Marktanteils für aufrichtbare Funktionsstörungdrogen schließlich zu ergreifen. Anteile von Icos` Konkurrenten waren auch am Montag höher, wenn Pfizer 0.9 Prozent $27.39 hinzufügt, Bayer herauf 0.6 Prozent $32.04 und Glaxo, das 0.87 Prozent bis $43.02 gewinnt. Diese Geschichte wurde von CBSMarketWatch geliefert. Für weitere Informationen sehen Sie www.cbsmarketwatch.com. Einkommen, Profitprognosen Aktien


gruß kurttilly

[Wunram]

genau

Lilly ICOS Celebrates a `Promising` First Year of Cialis(R) (tadalafil) in the U.S.

- American Men with ED Celebrate Their First 365 days with 36-Hour Cialis -

BOTHELL, Wash. and INDIANAPOLIS, Ind., Dec. 3 /PRNewswire-FirstCall/ -- Lilly ICOS`s (NYSE: LLY; Nasdaq: ICOS) Cialis(R) (tadalafil)(1), the only erectile dysfunction (ED) treatment clinically proven to both act fast and work up to 36 hours for most men, is marking its first year of availability in the United States.

Since its approval, Cialis has increased its share of total prescriptions every month in the U.S. For the week ended November 19, 2004, Cialis held a 21.7 percent share of new and 19.1 percent of total U.S. oral ED treatment prescriptions.(2) Cialis had a very strong initial launch and now continues to gain share against market leader Viagra(R) (sildenafil citrate).

"It`s been a tremendous first year for Cialis," said Matt Beebe, Cialis U.S. Brand Team Leader. "We started the year with a clear strategy: educate health care professionals and then men with ED about the benefits of Cialis and how it can help them. Do that, and many men will choose Cialis as their ED treatment. We`ve said all along that because Cialis gives a man and his partner up to 36 hours to choose the moment for intimacy that is right for them, it will be very successful in the ED marketplace."

Memorable Moments

Cialis was approved in the U.S. on November 21, 2003. The first year of Cialis in the U.S. has included several memorable milestones:

* November 11, 2003 Cialis named one of TIME Magazine`s "Coolest
Inventions"
* January 5, 2004 Cialis debuted as a PGA Tour sponsor at the
Mercedes Championships in Maui, Hawaii
* February 1, 2004 Cialis television advertising campaign kicked-off
during Super Bowl XXXVIII
* February 27, 2004 Cialis surpassed Levitra in new prescriptions,
though Cialis launched several months later
* May 18, 2004 Lilly ICOS announced title sponsorship of Cialis
Western Open
* July 12, 2004 The Cialis Promise program launched with national
advertising
* September 27, 2004 Cialis awarded "2004 Best Launch of the Year" by
the Pharmaceutical Marketing Congress
* November 10, 2004 Cialis awarded "New Brand of the Year" by DTC
Perspectives Magazine

The Cialis Promise Program
Lilly ICOS broke more new ground in 2004 by launching "The Cialis Promise," a program that is a first-of-its-kind among ED treatments. The Cialis Promise offers a free trial of Cialis to men with ED who have never used Cialis. If they like Cialis, Lilly ICOS will pay for another free Cialis sample. If they don`t, Lilly ICOS will pay for a sample of the prescription ED tablet of their choice. In the first nineteen weeks of the Cialis Promise program, a vast majority of men who completed the program and requested a second free sample voucher chose Cialis. Full program details are provided at www.cialis.com .

A Promising Future

Cialis continues its market share growth in the U.S. and worldwide. In September 2004 in France and Australia, Cialis had a 38 percent share of the ED market. In many other countries where Cialis has been approved, it continues steady growth against Viagra.

"More than three million men around the world have tried Cialis. Men tell us they want an ED treatment that offers a long window of effectiveness," said Leonard Blum, ICOS Vice President, Sales and Marketing. "In addition to Cialis working for up to 36 hours, it also works fast. These benefits offer couples spontaneity and allow intimacy to happen when the moment is right for them, without feeling pressure to perform in a short amount of time."

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. As of 2004, it is estimated that approximately 189 million men worldwide will report having ED.(3) Experts believe that 80 - 90 percent of ED cases are related to a physical or medical condition, like diabetes, cardiovascular diseases, and prostate cancer treatment, while 10 - 20 percent are due to psychological causes.(4,5) In many cases, however, both psychological and physical factors contribute to the condition.(6)

About Cialis

Cialis, approved by the FDA in November 2003 for the treatment of erectile dysfunction, is the only oral ED treatment shown to improve erectile function up to 36 hours in most men. Cialis can be taken without regard to food. The absorption of Cialis is not reduced by food, including high-fat foods. Cialis is currently available in approximately 100 countries, including Australia, Brazil, Mexico, Canada, the United States and countries throughout Europe. More than three million patients worldwide have been treated with Cialis since its first introduction in February 2003.

Cialis is available by prescription only and is not for everyone. Men taking nitrates, often used for chest pain, or certain alpha-blockers for prostate problems or high blood pressure, should not take Cialis. Such combinations could cause a sudden, unsafe drop in blood pressure.

Men should discuss their health status with their doctors to ensure Cialis is right for them and that they are healthy enough for sexual activity.

The most common side effects with Cialis were headache, upset stomach, delayed backache or muscle ache. Although rare, men who experience an erection for more than four hours should seek immediate medical attention. Men should not drink alcohol in excess with Cialis. Cialis does not protect a man or his partner from sexually transmitted diseases, including HIV.

Individual results may vary. Cialis studies were not designed to assess multiple intercourse attempts after a single dose.

For full patient information, visit www.cialis.com .

About Lilly ICOS LLC

Lilly ICOS LLC, a joint venture between ICOS Corporation (Nasdaq: ICOS) and Eli Lilly and Company (NYSE: LLY), developed tadalafil for the treatment of erectile dysfunction.

Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs. Additional information about Lilly is available at www.lilly.com .

P-LLY

ICOS Corporation, a biotechnology company headquartered in Bothell, Washington, is dedicated to bringing innovative therapeutics to patients. ICOS is marketing its first product, Cialis (tadalafil), through Lilly ICOS LLC. ICOS is working to develop treatments for serious unmet medical conditions such as chronic obstructive pulmonary disease, benign prostatic hyperplasia, cancer and inflammatory diseases.

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by the management of ICOS and Lilly. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, competitive, governmental, technological, legal and other factors discussed in the two companies` respective filings with the Securities and Exchange Commission, which may affect the business and prospects of the two companies and Lilly ICOS. Results and the timing and outcome of events may differ materially from those expressed or implied by the forward-looking statements in this press release. More specifically, there can be no assurance that Cialis will achieve commercial success or that competing products will not pre-empt market opportunities that might exist for the product.

(1) Cialis(R) is a registered trademark of Lilly ICOS LLC. All other trademarks are the property of their respective owners.

(2) IMS National Prescription Audit Plus7(TM), November 2004.

(3) Data were extrapolated from Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ. Impotence and its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study, Journal of Urology. Vol. 151, 54-61, January 1994 and World Population Projection Program Of United Nations (2002 Revision) with indirect standardization.

(4) Shabsigh, R. (2002). Back To Great Sex: Overcome ED and Reclaim Lost Intimacy. New York: Kensington.

(5) Diseases and Conditions: Impotence,
http://www.impotence.org/FAQ/index.asp . Data accessed 11.20.03

(6) Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-1813.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO )

SOURCE Lilly ICOS LLC
-0- 12/03/2004
/CONTACT: Carole Copeland of Lilly, [phone]; or Lacy Fitzpatrick
of ICOS, [phone]/
/Photo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO
PRN Photo Desk, [e-mail]/
(LLY ICOS)

CO: Lilly ICOS LLC; ICOS Corporation; Eli Lilly and Company
ST: Indiana, Washington